



***** INVENTOR RESULTS *****

=> d his 143

(FILE 'HCAPLUS' ENTERED AT 11:25:21 ON 17 JUL 2008)
L43 8 S L42 NOT L26=> d que 143
L20 STR

Structure attributes must be viewed using STN Express query preparation:

Uploading L8.str



chain nodes :
 10 11 12 14 15
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 7-15 9-10 10-11 10-12 10-14
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :
 6-9 7-15 8-9 9-10 10-11 10-12
 exact bonds :
 5-7 7-8 10-14
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 14:Atom 15:CLASS

L22 314 SEA FILE=REGISTRY SSS FUL L20
 L26 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L22
 L27 80 SEA FILE=HCAPLUS ABB=ON PLU=ON ("LUBISCH W"/AU OR "LUBISCH
 WILFRIED"/AU)
 L28 67 SEA FILE=HCAPLUS ABB=ON PLU=ON ("HORNBURGER W"/AU OR
 "HORNBURGER W F"/AU OR "HORNBURGER WILFRIED"/AU OR "HORNBURGER
 WILFRIED B"/AU)
 L29 42 SEA FILE=HCAPLUS ABB=ON PLU=ON ("OOST T"/AU OR "OOST
 THORSTEN"/AU OR "OOST THORSTEN K"/AU)
 L30 50 SEA FILE=HCAPLUS ABB=ON PLU=ON ("SAUER DARYL"/AU OR "SAUER
 DARYL R"/AU OR "SAUER DARYL RICHARD"/AU)
 L31 118 SEA FILE=HCAPLUS ABB=ON PLU=ON ("UNGER LILIANE"/AU OR "UNGER
 LILIANE DR"/AU OR "UNGER LILIANE V"/AU)
 L32 82 SEA FILE=HCAPLUS ABB=ON PLU=ON ("WERNET W"/AU OR "WERNET
 WOLFGANG"/AU OR "WERNET WOLFGANG"/AU)
 L33 52 SEA FILE=HCAPLUS ABB=ON PLU=ON "GENESTE HERVE"/AU
 L34 24 SEA FILE=HCAPLUS ABB=ON PLU=ON L27 AND ((L28 OR L29 OR L30
 OR L31 OR L32 OR L33))
 L35 29 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND ((L29 OR L30 OR L31
 OR L32 OR L33))
 L36 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L29 AND ((L30 OR L31 OR L32
 OR L33))
 L37 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L30 AND ((L31 OR L32 OR L33))
 L38 27 SEA FILE=HCAPLUS ABB=ON PLU=ON L31 AND ((L32 OR L33))
 L39 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L32 AND L33
 L40 51 SEA FILE=HCAPLUS ABB=ON PLU=ON (L34 OR L35 OR L36 OR L37 OR
 L38 OR L39)
 L42 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L40 AND (VASOPRESSIN? OR
 OXYTOCIN?)
 L43 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L42 NOT L26

=> d his 163

(FILE 'MEDLINE, BIOSIS, DRUGU, EMBASE' ENTERED AT 11:37:51 ON 17 JUL 2008)
 L63 12 DUP REM L62 (18 DUPLICATES REMOVED)
 SAVE TEMP L63 CHA211MULTIN/A

FILE 'STNGUIDE' ENTERED AT 11:44:22 ON 17 JUL 2008

=> d que 163
 L45 39 SEA LUBISCH WILFRIED/AU

L46 46 SEA HORNBERGER WILFRIED/AU
 L47 21 SEA OOST THORSTEN K/AU
 L48 1 SEA SAUER DARYL RICHARD/AU
 L49 57 SEA UNGER LILIANE/AU
 L50 21 SEA WERNET WOLFGANG/AU
 L51 38 SEA GENESTE HERVE/AU
 L52 6 SEA L45 AND ((L46 OR L47 OR L48 OR L49 OR L50 OR L51))
 L53 21 SEA L46 AND ((L47 OR L48 OR L49 OR L50 OR L51))
 L54 0 SEA L47 AND ((L48 OR L49 OR L50 OR L51))
 L55 0 SEA L48 AND ((L49 OR L50 OR L51))
 L56 16 SEA L49 AND ((L50 OR L51))
 L57 9 SEA L50 AND L51
 L59 39 SEA ((L52 OR L53 OR L54 OR L55 OR L56 OR L57)) AND (DRUG# OR
 PRODRUG# OR PHARMAC? OR MEDICA?)
 L62 30 SEA L59 AND (ANTIDEPRESS? OR ANTAGON?)
 L63 12 DUP REM L62 (18 DUPLICATES REMOVED)

=> dup rem 143 163
 FILE 'HCAPLUS' ENTERED AT 11:45:17 ON 17 JUL 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:45:17 ON 17 JUL 2008

FILE 'BIOSIS' ENTERED AT 11:45:17 ON 17 JUL 2008
 Copyright (c) 2008 The Thomson Corporation
 PROCESSING COMPLETED FOR L43
 PROCESSING COMPLETED FOR L63
 L64 20 DUP REM L43 L63 (0 DUPLICATES REMOVED)
 ANSWERS '1-8' FROM FILE HCAPLUS
 ANSWERS '9-17' FROM FILE MEDLINE
 ANSWERS '18-20' FROM FILE BIOSIS

=> d 164 1-8 ibib abs hitstr; d 164 9-20 ibib ab

L64 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:824753 HCAPLUS Full-text
 TITLE: Substituted oxindole derivatives and their use as
 vasopressin receptor ligands
 INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste,
 Herve; Braje, Wilfried Martin; Wernet,
 Wolfgang; Unger, Liliane;
 Hornberger, Wilfried; Lubisch,
 Wilfried
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 98pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080973	A1	20080710	WO 2007-EP64622	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				

KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 MB, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DE 2006-102006062505A 20061230
 DE 2006-102006062506A 20061230
 DE 2006-102006062507A 20061230
 DE 2006-102006062508A 20061230

AB The present invention relates to novel oxindole derivs. of the general formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent.

L64 ANSWER 2 OF 20 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2008:824752 HCPLUS Full-text

TITLE:

Substituted oxindole derivative and its use as a vasopressin receptor modulator

INVENTOR(S):

Netz, Astrid; Oost, Thorsten; Geneste, Herve; Braje, Wilfried Martin; Wernet, Wolfgang; Unger, Liliane; Bornberger, Wilfried; Lubisch, Wilfried

PATENT ASSIGNEE(S):

Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE:

PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080972	A1	20080710	WO 2007-EP64621	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

DE 2006-102006062506A 20061230

AB The present invention relates to novel oxindole derivs. of the formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent.

L64 ANSWER 3 OF 20 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

2008:824755 HCPLUS Full-text

TITLE:

Substituted oxindole derivative and its use as a vasopressin receptor ligand

INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Hervé; Braje, Wilfried Martin; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Lubisch, Wilfried

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 37pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080971	A1	20080710	WO 2007-EP64620	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, RU, TJ, TM				

PRIORITY APPLN. INFO.: DE 2006-102006062507A 20061230

AB The present invention relates to novel oxindole derivs. of the formula (I) to medicaments comprising them and to their use for the prophylaxis and/or treatment of diseases vasopressin dependent.

L64 ANSWER 4 OF 20 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:824754 HCPLUS Full-text
 TITLE: Substituted oxindole derivative and its use as a vasopressin receptor ligand
 INVENTOR(S): Netz, Astrid; Oost, Thorsten; Geneste, Hervé; Braje, Wilfried Martin; Wernet, Wolfgang; Unger, Liliane; Hornberger, Wilfried; Lubisch, Wilfried

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 37pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080970	A1	20080710	WO 2007-EP64619	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				


TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DE 2006-102006062508A 20061230
 AB The present invention relates to novel oxindole derivs. of the formula (I) to
 medicaments comprising them and to their use for the prophylaxis and/or
 treatment of diseases vasopressin dependent.

L64 ANSWER 5 OF 20 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:287977 HCPLUS Full-text
 DOCUMENT NUMBER: 148:331683
 TITLE: Substituted benzimidazolone derivatives, medicaments
 comprising them and their preparation and use in the
 treatment of vasopressin-dependent disease
 INVENTOR(S): Arndt, Torsten; Oost, Thorsten; Lubisch,
 Wolfgang; Wernet, Wolfgang; Hornberger,
 Wilfried; Unger, Liliane; Ruiz Caro,
 Juliana
 PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany
 SOURCE: PCT Int. Appl., 219pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008025736	A1	20080306	WO 2007-EP58840	20070824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: DE 2006-102006040914A 20060826
 OTHER SOURCE(S): MARPAT 148:331683
 GI



AB The invention relates to benzimidazolone derivs. of the general formula I, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases. Compds. of formula I wherein A1 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-6 cycloalkyl, etc.; A2 is H, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkenyl, (un)substituted C1-6 alkynyl, and (un)substituted C3-6 cycloalkyl; B is (un)substituted (hetero)aromatic ring and (un)substituted partly (hetero)aromatic ring; R1 is H, Br, Cl, F, I, CN, CF3, OCFC3, OCHF2, (un)substituted C1-4 alkyl(oxy), etc.; R2 is H, (un)substituted C1-4 alkyl(oxy), Cl, F, CHF2 and CF3; R3 is CO2H and derivs., SO3H and derivs., CONH2 and derivs., SO2NH2 and derivs. C(NH)NH2 and derivs., etc.; and their tautomers, enantiomers, diastereoisomers, prodrugs, and physiol. tolerated salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their vasopressin V1B binding affinity (data given).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L-64 ANSWER 6 OF 20 HCAPLHS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2006:1011112 HCABPLUS Full-text

ACCESSION NUMBER:
DOCUMENT NUMBER:

DOCUMENT NUMBER: 140-57159
TITLE: Preparation of 1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones and related compounds as vasopressin V_{1B} receptor modulators

INVENTOR(S): Oost, Thorsten; Lubisch, Wilfried;
Wernet, Wolfgang; Hornberger, Wilfried

PATENT ASSIGNEE(S): ; Unger, Liliane
Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl.
CODEN: PIXXD2


DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

WO 2006100082 A2 20060928 WO 2006-EP2685 20060323
WO 2006100082 A3 20061207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GS, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 DE 102005014628 A1 20060928 DE 2005-102005014628 20050326
 DE 102005015957 A1 20061005 DE 2005-102005015957 20050331
 CA 2602194 A1 20060928 CA 2006-2602194 20060323
 EP 1861392 A2 20071205 EP 2006-723672 20060323
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
 MX 200711693 A 20080311 MX 2007-11693 20070921
 PRIORITY APPLN. INFO.: US 2005-664759P P 20050324
 DE 2005-102005014628A 20050326
 DE 2005-102005015957A 20050331
 WO 2006-EP2685 W 20060323

OTHER SOURCE(S): CASREACT 145:377199; MARPAT 145:377199
 GI



AB Title compds. I [A = aromatic, heteroarom., etc.; B = aromatic, heteroarom., etc.; R1 = H, halo, CN, etc.; R2 = H, alkyl, O-alkyl, etc.; Y = N(Y1)C(Y2Y3Y4); Y1 = H, alkyl, haloalkyl; Y2 = H, phenyl; Y3 = H, alkyl, haloalkyl; Y4 = H, CO-alkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, phenylsulfonylindolone II was prepared from 3-hydroxy-4-iodobenzaldehyde in 6-steps. In vasopressin V1B receptor binding assays, 59-examples of compds. I exhibited Ki values <100 nM.

L64 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1006700 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 145:377197
 TITLE: Preparation of 1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones and related compounds as vasopressin V1B receptor modulators
 INVENTOR(S): Lubisch, Wilfried; Coest, Thorsten;
 Wernet, Wolfgang; Hornberger, Wilfried;
 Unger, Liliane; Geneste, Herve
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 61pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100081	A2	20060928	WO 2006-EP2684	20060323
WO 2006100081	A3	20061207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102005014904	A1	20070201	DE 2005-102005014904	20050326
CA 2602174	A1	20060928	CA 2006-2602174	20060323
EP 1866304	A2	20071219	EP 2006-707637	20060323
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
MX 200711695	A	20080311	MX 2007-11695	20070921
PRIORITY APPLN. INFO.:			US 2005-664899P	P 20050324
			DE 2005-102005014904A	20050326
			WO 2006-EP2684	W 20060323

OTHER SOURCE(S): CASREACT 145:377197; MARPAT 145:377197

GI





AB Title compds. I [P1 = (CH₂)_n; P2 = (CH₂)_m; n = 2, 3; m = 1, 2; Y₁ = C, N; Y₂ = C, N; X = O, NH, N-CN; W = O, CH₂, NH; Z = mono- bi- or tricyclic heteroarom. with provisos; B = mono- bi- or tricyclic heteroarom. with provisos; R3 = H, F, Cl, etc.; R2 = O-alkyl, alkyl, Cl; R1 = H, alkyl, O-alkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, phenylsulfonylindolone II was prepared from 5-chloroisatin in 4-steps. In vasopressin V_{1B} receptor binding assays, 11-examples of compds. I exhibited K_i values <500 nM.

L64 ANSWER 8 OF 20 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:284200 HCPLUS Full-text
 DOCUMENT NUMBER: 142:355286
 TITLE: Preparation of heteroaryl-substituted
 1,3-dihydroindol-2-one derivatives and medicaments
 containing them
 INVENTOR(S): Lubisch, Wilfried; Hornberger,
 Wilfried; Oost, Thorsten K.;
 Sauer, Daryl Richard; Unger, Liliane
 ; Wernet, Wolfgang
 PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
 SOURCE: U.S. Pat. Appl. Publ., 24 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050070718	A1	20050331	US 2003-675300	20030930
CA 2537598	A1	20050407	CA 2004-2537598	20040930
WO 2005030755	A1	20050407	WO 2004-EP10940	20040930
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 166793	A1	20060614	EP 2004-765719	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007507456	T	20070329	JP 2006-530059	20040930
MX 2006PA03558	A	20060831	MX 2006-PA3558	20060530
US 20070021607	A1	20070125	US 2006-440569	20060525
US 20070185126	A1	20070809	US 2007-574211	20070122
PRIORITY APPLN. INFO.:			US 2003-675300	A 20030930
			WO 2004-EP10940	W 20040930

OTHER SOURCE(S): CASREACT 142:355286; MARPAT 142:355286
 GI



AB The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivs. of the formula (I) [A = each (un)substituted aromatic heteromonocyclic or aromatic or partially aromatic heterobicyclic ring, where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups; R3, R4, R6, R7 = H, Cl, Br, iodo, F, cyano, CF3, OCF3, NO2, OH, Cl-4 alkoxy, PhO, phenyl-Cl-4 alkenyloxy, Ph, Cl-6 alkyl, C2-6 alkenyl, C2-6 alkyynyl, NH2, mono- or di(Cl-4 alkyl)amino; or R3 and R4 are connected to give -CH:CH-CH:CH-, -(CH2)4- or -(CH2)3-; R5 = a radical (W)-(X)-(Y)-Z; where W = Cl-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, O, O-(Cl-4 alkylene), S, S-(Cl-4 alkylene), N-(un)substituted NH or NH-(Cl-4 alkylene), a bond; X = CO, CO-O, SO2, each (un)substituted NH, NH-CO, NH-SO2, or CO-NH, a bond; Y = Cl-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, a bond; Z = H, E, each (un)substituted OH, NH2, or SH; where E = (un)substituted, unsatd., saturated or partially unsatd. mono, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms; I and their tautomeric forms, enantiomeric and diastereomeric forms, and prodrugs thereof. These compds. can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases, for example for the treatment of (1) depressions and/or bipolar disorders such as dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders, (2) anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, posttraumatic disorders, acute stress disorders and/or social phobia, (3) memory disorders and/or Alzheimer's disease, (4) psychoses and/or psychotic disorders, or (5) Cushing's syndrome. Thus, (2S,4R)-4-hydroxypyrrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.78 g, 4.0 mmol) was added to a solution of 3-(benzothiazol-2-yl)-3,5-dichloro-1,3-dihydroindol-2-one, in a mixture of dichloromethane 9, THF 2 and diisopropylethylamine 2 mL and the reaction mixture was stirred at room temperature for 48 h to give, after workup and silica gel chromatog., two diastereomers of (2S,4R)-1-[3-(Benzothiazol-2-yl)-5-chloro-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxypyrrrolidine-2-carboxylic acid dimethylamide. NaH (12 mg 60% dispersion in mineral oil) was added to an ice-cold solution of the less polar diastereomer product from the above (115 mg, 0.25 mmol) in DMF (1.5 mL). The reaction mixture was stirred at 0° for 1 h and then treated with 2,4-dimethoxyphenylsulfonyl chloride (71 mg, 0.3 mmol), and stirred at room temperature for 1 h to give, after workup and silica gel chromatog., 93 mg (+)-(2S,4R)-1-[3-(benzothiazol-2-yl)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-

hydroxypyrrolidine-2-carboxylic acid dimethylamide (II) as a white solid. II
in vitro binding affinity to vasopressin VIb receptor with <50 nM.

L64 ANSWER 9 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2008052109 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 18068982
 TITLE: Design and synthesis of novel potent and selective integrin
alpha/nabeta3 antagonists--novel synthetic routes
to isoquinolinone, benzoxazinone, and quinazolinone
acetates.
 AUTHOR: Seitz Werner; Geneste Herve; Backfisch Gisela;
Delzer Jürgen; Graef Claudia; Hornberger Wilfried
; Kling Andreas; Subkowski Thomas; Zimmermann Norbert
 CORPORATE SOURCE: BASF AG, Main Research Laboratory, D-67056 Ludwigshafen,
Germany.
 SOURCE: Bioorganic & medicinal chemistry letters, (2008 Jan 15)
Vol. 18, No. 2, pp. 527-31. Electronic Publication:
2007-11-28.
 Journal code: 9107377. E-ISSN: 1464-3405.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200805
 ENTRY DATE: Entered STN: 23 Jan 2008
 Last Updated on STN: 28 May 2008
 Entered Medline: 27 May 2008
 AB An unexpected ring contraction of benzazepinone based alpha(nu)beta(3)
antagonists led to the design of quinolinone-type derivatives. Novel and
efficient synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone
acetates were established. Nanomolar alpha(nu)beta(3) antagonists based on
these new scaffolds were prepared. Moreover, benzoxazinones 15a and 15b
exhibited high microsomal stability and good permeability.

L64 ANSWER 10 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2006113054 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 16439127
 TITLE: Synthesis and SAR of highly potent and selective dopamine
D3-receptor antagonists: variations on the
1H-pyrimidin-2-one theme.
 AUTHOR: Geneste Hervé; Amberg Wilhelm; Backfisch Gisela;
Beyerbach Armin; Braje Wilfried M; Delzer Jürgen; Haupt
Andreas; Hutchins Charles W; King Linda L; Sauer Daryl R;
Unger Liliane; Wernet Wolfgang
 CORPORATE SOURCE: Abbott GmbH & Co. KG, Discovery Research, D-67008
Ludwigshafen, Germany.. herve.geneste@abbott.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2006 Apr 1) Vol.
16, No. 7, pp. 1934-7. Electronic Publication: 2006-01-24.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200607
 ENTRY DATE: Entered STN: 28 Feb 2006
 Last Updated on STN: 20 Jul 2006
 Entered Medline: 19 Jul 2006

AB In our efforts to further pursue one of the most selective dopamine D(3)-receptor antagonists reported to date, we now describe the synthesis and SAR of novel and highly selective dopamine D(3) antagonists based on a 1H-pyridin-2-one or on a urea scaffold. The most potent compounds exhibited K(i) values toward the D(3) receptor in the nano- to subnanomolar range and high selectivity versus the related D(2) dopamine receptor. Thus, 1H-pyridin-2-one 7b displays oral bioavailability (F=37%) as well as brain penetration (brain plasma ratio 3.7) in rat. Within the urea series, an excellent D(3) versus D(2) selectivity (>100-fold) could be achieved by removal of one NH group (compound 6), although bioavailability (rat) was suboptimal (F<10%). These data significantly enhance our understanding of the D(3) pharmacophore and are expected to lead to novel approaches for the treatment of schizophrenia.

L64 ANSWER 11 OF 20 MEDLINE on STN

ACCESSION NUMBER: 2005687876 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 16271293
 TITLE: Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.geneste@abbott.com.
 AUTHOR: Geneste Herve; Backfisch Gisela; Braje Wilfried; Delzer Jurgens; Haupt Andreas; Hutchins Charles W; King Linda L; Lubisch Wilfried; Steiner Gerd; Teschendorf Hans-Jurgen; Unger Liliane; Werner Wolfgang
 CORPORATE SOURCE: Abbott GmbH & Co. KG, Discovery Research, D-67008 Ludwigshafen, Germany.
 SOURCE: Bioorganic & medicinal chemistry letters, (2006 Feb) Vol. 16, No. 3, pp. 658-62. Electronic Publication: 2005-11-02. Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200603
 ENTRY DATE: Entered STN: 28 Dec 2005
 Last Updated on STN: 29 Mar 2006
 Entered Medline: 28 Mar 2006

AB The synthesis and SAR of novel and selective dopamine D(3)-receptor antagonists based on a 3,4-dihydro-1H-quinolin-2-one, a 1,3,4,5-tetrahydrobenzo[b]azepin-2-one, 1H-quinoline-2,4-dione or a 3,4-dihydro-1H-benzo[b]azepine-2,5-dione scaffold are discussed. A706149 (2.15mg/kg, po) antagonizes PD 128907-induced huddling deficits in rat, a social interaction paradigm.

L64 ANSWER 12 OF 20 MEDLINE on STN

ACCESSION NUMBER: 2005687902 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 16290141
 TITLE: Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives.
 AUTHOR: Geneste Herve; Backfisch Gisela; Braje Wilfried; Delzer Jurgens; Haupt Andreas; Hutchins Charles W; King Linda L; Kling Andreas; Teschendorf Hans-Jurgen; Unger Liliane; Werner Wolfgang
 CORPORATE SOURCE: Abbott GmbH & Co. KG, Discovery Research, D-67008 Ludwigshafen, Germany.. herve.geneste@abbott.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2006 Feb) Vol. 16, No. 3, pp. 490-4. Electronic Publication: 2005-11-11.

PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200603
 ENTRY DATE: Entered STN: 28 Dec 2005
 Last Updated on STN: 29 Mar 2006
 Entered Medline: 28 Mar 2006
AB The synthesis and SAR of novel highly potent and selective dopamine D(3)-receptor antagonists based on a 1H-pyrimidin-2-one scaffold are described. A-690344 antagonized PD 128907-induced huddling deficits in rat (ED(50) 6.1mg/kg po), a social interaction paradigm.

L64 ANSWER 13 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2005582219 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 16219465
 TITLE: Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.
 AUTHOR: Kling Andreas; Lange Udo E W; Mack Helmut; Bakker Margot H M; Drescher Karla U; Hornberger Wilfried; Hutchins Charles W; Moller Achim; Muller Reinhold; Schmidt Martin; Unger Liliane; Wicke Karsten; Scheilhaas Kurt; Steiner Gerd
 CORPORATE SOURCE: Neuroscience Discovery, Abbott GmbH & Co. KG, D-67008 Ludwigshafen, Germany.. andreas.kling@abbott.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2005 Dec 15) Vol. 15, No. 24, pp. 5567-73. Electronic Publication: 2005-10-10.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200606
 ENTRY DATE: Entered STN: 3 Nov 2005
 Last Updated on STN: 28 Jun 2006
 Entered Medline: 27 Jun 2006

AB Novel 5-HT(1) autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT(1A) and 5-HT(1B) receptors. Strategies for the development of dual 5-HT(1A) and 5-HT(1B) antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT(1A) and the 5-HT(1B) receptors and was characterized further with respect to selectivity, electrically stimulated [³(3)H]5-HT release and in vivo efficacy.

L64 ANSWER 14 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2003115131 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 12628659
 TITLE: Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin alphaVbeta3 antagonists.
 AUTHOR: Kling Andreas; Backfisch Gisela; Delzer Jurgen; Geneste Herve; Graef Claudia; Hornberger

CORPORATE SOURCE: Wilfried; Lange Udo E W; Lauterbach Arnulf; Seitz Werner; Subkowski Thomas
 Neuroscience, Medicinal Chemistry, Abbott GmbH and Co KG,
 Discovery Research, D-67008, PO Box 210805, Ludwigshafen,
 Germany.
 SOURCE: Bioorganic & medicinal chemistry, (2003 Apr 3) Vol. 11, No.
 7, pp. 1319-41.
 Journal code: 9413298. ISSN: 0968-0896.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: (IN VITRO)
 LANGUAGE: Journal; Article; (JOURNAL ARTICLE)
 English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200311
 ENTRY DATE: Entered STN: 12 Mar 2003
 Last Updated on STN: 11 Nov 2003
 Entered Medline: 10 Nov 2003

AB The design and synthesis of novel integrin alpha(V)beta(3) antagonists based on a 1,5- or 2,5-substituted tetrahydrobenzazepinone core is described. In vitro activity of respective compounds was determined via alpha(V)beta(3) binding assay, and selected derivatives were submitted to further characterization in functional cellular assays. SAR was obtained by modification of the benzazepinone core, variation of the spacer linking guanidine moiety and core, and modification of the guanidine mimetic. These efforts led to the identification of novel alpha(V)beta(3) inhibitors displaying potency in the subnanomolar range, selectivity versus alpha(IIb)beta(3) and functional efficacy in relevant cellular assays. A method for the preparation of enantiomerically pure derivatives was developed, and respective enantiomers evaluated in vitro. Compounds 31 and 37 were assessed for metabolic stability, resorption in the Caco-2 assay and pharmacokinetics.

L64 ANSWER 15 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2002720401 MEDLINE [Full-text](#)
 DOCUMENT NUMBER: PubMed ID: 12482416
 TITLE: Highly potent and selective alphaVbeta3-receptor
 antagonists: solid-phase synthesis and SAR of
 1-substituted 4-amino-1H-pyrimidin-2-ones.
 AUTHOR: Zechel Christian; Backfisch Gisela; Delzer Jurgen;
 Genste Herve; Graef Claudia; Hornberger
 Wilfried; Kling Andreas; Lange Udo E W; Lauterbach
 Arnulf; Seitz Werner; Subkowski Thomas
 CORPORATE SOURCE: BASF AG, D-67056 Ludwigshafen, Germany..
zechel_christian@lilly.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2003 Jan 20)
 Vol. 13, No. 2, pp. 165-9.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200307
 ENTRY DATE: Entered STN: 18 Dec 2002
 Last Updated on STN: 18 Jul 2003
 Entered Medline: 17 Jul 2003

AB Solid-phase synthesis and SAR of alpha(V)beta(3)-receptor antagonists based on a N(1)-substituted 4-amino-1H-pyrimidin-2-one scaffold are described. The most potent compounds exhibited IC(50) values towards alpha(V)beta(3) in the nano- to subnanomolar range and high selectivity versus related integrins like

alpha(IIb)beta(3). For selected examples efficacy in functional cellular assays was demonstrated.

L64 ANSWER 16 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2002252856 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 11992781
 TITLE: Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.
 AUTHOR: Lange Udo E W; Backfisch Gisela; Delzer Jurgen; Genste Herve; Graef Claudia; Hornberger Wilfried; Kling Andreas; Lauterbach Arnulf; Subkowski Thomas; Zechel Christian
 CORPORATE SOURCE: BASF AG, D-67056, Ludwigshafen, Germany..
 udo.lange@basf-ag.de
 SOURCE: Bioorganic & medicinal chemistry letters, (2002 May 20) Vol. 12, No. 10, pp. 1379-82.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200209
 ENTRY DATE: Entered STN: 7 May 2002
 Last Updated on STN: 18 Sep 2002
 Entered Medline: 17 Sep 2002

AB Solid-phase synthesis and SAR of integrin alpha(V)beta3-receptor antagonists containing a urea moiety as non-basic guanidine mimetic are described. The most potent compounds exhibited IC(50) values towards alpha(V)beta3 in the nanomolar range and high selectivity versus related integrins like alpha(IIb)beta3. For selected examples efficacy in functional cellular assays is demonstrated.

L64 ANSWER 17 OF 20 MEDLINE on STN
 ACCESSION NUMBER: 2002147342 MEDLINE Full-text
 DOCUMENT NUMBER: PubMed ID: 11814816
 TITLE: Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel potent and selective alpha(V)beta(3) antagonists.
 AUTHOR: Kling Andreas; Backfisch Gisela; Delzer Jurgen; Genste Herve; Graef Claudia; Holzenkamp Uta; Hornberger Wilfried; Lange Udo E W; Lauterbach Arnulf; Mack Helmut; Seitz Werner; Subkowski Thomas
 CORPORATE SOURCE: Knoll GmbH, D-67008 Ludwigshafen, Germany..
 andreas.kling@abbott.de
 SOURCE: Bioorganic & medicinal chemistry letters, (2002 Feb 11) Vol. 12, No. 3, pp. 441-6.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200206
 ENTRY DATE: Entered STN: 8 Mar 2002
 Last Updated on STN: 19 Jun 2002
 Entered Medline: 18 Jun 2002

AB Synthesis and SARS of new integrin alpha(V)beta(3) antagonists based on an N-substituted dibenzazepinone scaffold are described. Variation of spacer and guanidine mimetic led to potent compounds exhibiting an IC(50) towards

alpha(V)beta(3) in the nanomolar range, high selectivity versus integrin alpha(IIb)beta(3) and efficacy in functional cellular assays.

L64 ANSWER 18 OF 20 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2008:392094 BIOSIS Full-text

DOCUMENT NUMBER: PREV200800392093

TITLE: N-[(piperazinyl)hetaryl]arylsulfonamide compounds.

AUTHOR(S): Anonymous; Braje, Wilfried M. [Inventor]; Haupt, Andreas [Inventor]; Lubisch, Wilfried [Inventor]; Grandel, Roland [Inventor]; Drescher, Karla [Inventor]; Geneste, Herve [Inventor]; Unger, Liliane [Inventor]; Sauer, Daryl R. [Inventor]; Turner, Sean C. [Inventor]

CORPORATE SOURCE: Rintein, Germany

ASSIGNEE: Abbott GmbH and Co KG

PATENT INFORMATION: US 07320979 20080122

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (JAN 23 2008)

CODEN: OGUPET. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 16 Jul 2008

Last Updated on STN: 16 Jul 2008

AB The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula I in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R(a) which is/are selected, independently of each other, from halogen, CN, NO₂, CO₂R, COR₅, C-1-C-4-alkyl and C-1-C-4-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R-b, which is/are selected from halogen, NO₂, CN, CO₂R, COR₅, C-1-C-6-alkyl, C-2-C-6-alkenyl, C-2-C-6-alkynyl, C-3-C-6-cycloalkyl, C-3-C-6-cycloalkyl-C-1-C-4-alkyl and C-1-C-4-haloalkyl, with it also being possible for two radicals R(b) which are bonded to adjacent C atoms of Ar to be together C-3-C-4-alkylene; R(1) is hydrogen, C-1-C-4-alkyl, C-1-C-4-haloalkyl, C-3-C-6-cycloalkyl, C-3-C-6-cycloalkyl-C-1-C-4-alkyl, C-1-C-4-hydroxalkyl, C-1-C-4-alkoxy-C-1-C-4-alkyl, C-3-C-4-alkenyl or C-3-C-4-alkynyl; with the radicals n, R-1, R-2, R-3, R(4) and R(5) having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D(3) receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.

L64 ANSWER 19 OF 20 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2007:22736 BIOSIS Full-text

DOCUMENT NUMBER: PREV200700033385

TITLE: Integrin receptors antagonists.

AUTHOR(S): Anonymous; Kling, Andreas [Inventor]; Geneste, Herve [Inventor]; Lange, Udo [Inventor]; Lauterbach, Arnulf [Inventor]; Graef, Claudia Isabella [Inventor]; Subkowski, Thomas [Inventor]; Holzenkamp, Uta [Inventor];

Mack, Helmut [Inventor]; Sadowski, Jens [Inventor];
 Hornberger, Wilfried [Inventor]; Laux, Volker
 [Inventor]

CORPORATE SOURCE: Mannheim, Germany

ASSIGNEE: Abbott GmbH and Co KG

PATENT INFORMATION: US 07105508 20060912

SOURCE: Official Gazette of the United States Patent and Trademark
 Office Patents, (SEP 12 2006)
 CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 27 Dec 2006
 Last Updated on STN: 27 Dec 2006

AB The invention relates to novel compounds which bind to integrin receptors, and
 to the preparation thereof and the use thereof as drugs.

L64 ANSWER 20 OF 20 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on
 STN

ACCESSION NUMBER: 1996:321917 BIOSIS [Full-text](#)

DOCUMENT NUMBER: PREV199699044273

TITLE: Discovery and optimization of a novel class of orally
 active nonpeptidic endothelin-A receptor
 antagonists.

AUTHOR(S): Riechers, Hartmut [Reprint author]; Albrecht, Hans-Peter;
 Amberg, Willi; Baumann, Ernst; Bernard, Harald; Bohm,
 Hans-Joachim; Klinge, Dagmar; Kling, Andreas; Mueller,
 Stefan; Raschack, Manfred; Unger, Liliane;
 Walker, Nigel; Wernet, Wolfgang

CORPORATE SOURCE: Hauptlaboratorium, BASF AG, 67056 Ludwigshafen, Germany

SOURCE: Journal of Medicinal Chemistry, (1996) Vol. 39, No. 11, pp.
 2123-2128.

CODEN: JMCMAR. ISSN: 0022-2623.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 11 Jul 1996
 Last Updated on STN: 11 Jul 1996

AB A novel class of endothelin-A receptor ligands was discovered by high-
 throughput screening. Lead structure optimization led to highly potent
 antagonists which can be synthesized in a short sequence. The compounds are
 endothelin-A-selective, are orally available, and show a long duration of
 action.


10/574211

***** QUERY RESULTS *****

=> d his 126


(FILE 'HCAPLUS' ENTERED AT 11:25:21 ON 17 JUL 2008)
L26 14 S L22

=> d que 126
L20 STR



Structure attributes must be viewed using STN Express query preparation:

Uploading L8.str



chain nodes :

10 11 12 14 15

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

7-15 9-10 10-11 10-12 10-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

6-9 7-15 8-9 9-10 10-11 10-12

exact bonds :

5-7 7-8 10-14

normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:CLASS 14:Atom 15:CLASS

L22 314 SEA FILE=REGISTRY SSS FUL L20
 L26 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L22

=> d 126 ibib ed abs hitstr hitind

L26 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:285994 HCAPLUS Full-text
 DOCUMENT NUMBER: 148:308179
 TITLE: Substituted oxindole derivatives and their use as
 vasopressin and/or oxytocin receptor ligands and their
 preparation
 INVENTOR(S): Geneste, Herve; Oost, Thorsten; Netz, Astrid;
 Hutchins, Charles W.; Wernet, Wolfgang; Lubisch,
 Wolfgang; Unger, Liliane; Hornberger, Wilfried
 PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany
 SOURCE: PCT Int. Appl., 124pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008025735	A1	20080306	WO 2007-EP58839	20070824
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102006040915	A1	20080320	DE 2006-102006040915	20060826
PRIORITY APPLN. INFO.:			DE 2006-102006040915A	20060826
OTHER SOURCE(S):	MARPAT	148:308179	US 2007-958591P	P 20070706
ED Entered STN:	07 Mar 2008			
GI				



AB The invention relates to oxindole derivs. of general formula I, to medicaments containing said derivs. and to their use for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases. Compds. of formula I wherein A is (un)substituted C6-10 aryl; B is (un)substituted aromatic/partially aromatic C6-10 (mono/bi)cyclic ring; R1 and R2 are independently H, Br, F, Cl, I, C1-4 alkylene-CN, CN, etc.; Y is (un)substituted alkylaminoalkylamino; and their tautomers, enantiomers, diastereoisomers, prodrugs, and physiol. acceptable salts thereof, are claimed. Example compound II was prepared by chlorination of 5-chloro-3-hydroxy-3-(2-methoxyphenyl)-1,3-dihydroindol-2-one the resulting 3,5-dichloro-3-(2-methoxyphenyl)-1,3-dihydroindol-2-one, underwent amination with 1-(pyridin-3-yl)piperazine hydrochloride to give 5-chloro-3-(2-methoxyphenyl)-3-(4-(pyridin-3-yl)piperazin-1-yl)dihydroindol-2-one, which underwent sulfonylation with 2,4-dimethoxybenzenesulfonyl chloride to give compound II. All the invention compds. were evaluated for their vasopressin and oxytocin binding affinity (some data given).


IT 2018-03-29-29

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted oxindole derivs. and their use as vasopressin and/or oxytocin receptor ligands and their preparation)

BN 1010133-93-3 HCAPLUS

1H-Indole-5-carbonitrile, 1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxy-5-methoxyphenyl)-2,3-dihydro-2-oxo-3-[{2-(4-pyridinylamino)ethyl}amino]-(CA INDEX NAME)



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1 2 63

	Section	CROSS-Reference(Sy, i, z, v)		
IT	1010131-35-7P	1010131-37-9P	1010131-39-1P	1010131-41-5P
	1010131-43-7P	1010131-45-9P	1010131-47-1P	1010131-49-3P
	1010131-51-7P	1010131-53-9P	1010131-55-1P	1010131-57-3P

1010131-59-5P	1010131-61-9P	1010131-63-1P	1010131-65-3P
1010131-67-5P	1010131-69-7P	1010131-71-1P	1010131-73-3P
1010131-75-5P	1010131-77-7P	1010131-79-9P	1010131-81-3P
1010131-83-5P	1010131-85-7P	1010131-87-9P	1010131-89-1P
1010131-92-6P	1010131-94-8P	1010131-96-0P	1010131-98-2P
1010132-00-9P	1010132-02-1P	1010132-04-3P	1010132-06-5P
1010132-12-3P	1010132-14-5P	1010132-16-7P	1010132-18-9P
1010132-20-3P	1010132-22-5P	1010132-24-7P	1010132-26-9P
1010132-28-1P	1010132-30-5P	1010132-34-9P	1010132-36-1P
1010132-38-3P	1010132-40-7P	1010132-42-9P	1010132-44-1P
1010132-46-3P	1010132-48-5P	1010132-50-9P	1010132-52-1P
1010132-54-3P	1010132-56-5P	1010132-58-7P	1010132-62-3P
1010132-64-5P	1010132-67-8P	1010132-69-0P	1010132-71-4P
1010132-74-7P	1010132-77-0P	1010132-80-5P	1010132-83-8P
1010132-86-1P	1010132-89-4P	1010132-91-8P	1010132-93-0P
1010132-95-2P	1010132-97-4P	1010132-99-6P	1010133-01-3P
1010133-03-5P	1010133-05-7P	1010133-07-9P	1010133-09-1P
1010133-11-5P	1010133-13-7P	1010133-15-9P	1010133-17-1P
1010133-19-3P	1010133-21-7P	1010133-23-9P	1010133-25-1P
1010133-27-3P	1010133-29-5P	1010133-31-9P	1010133-33-1P
1010133-35-3P	1010133-37-5P	1010133-39-7P	1010133-41-1P
1010133-43-3P	1010133-45-5P	1010133-47-7P	1010133-49-9P
1010133-51-3P	1010133-53-5P	1010133-56-8P	1010133-59-1P
1010133-62-6P	1010133-65-9P	1010133-68-2P	1010133-71-7P
1010133-73-9P	1010133-75-1P	1010133-78-4P	1010133-81-9P
1010133-84-2P	1010133-87-5P	1010133-89-7P	1010133-91-1P
1010133-93-3P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted oxindole derivs. and their use as vasopressin and/or oxytocin receptor ligands and their preparation)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 126 2-14 ibib ed abs hitstr hitind
 THE ESTIMATED COST FOR THIS REQUEST IS 75.53 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L26 ANSWER 2 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:619930 HCPLUS Full-text
 DOCUMENT NUMBER: 147:52806
 TITLE: Preparation of 1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones for the treatment of vasopressin dependent diseases
 INVENTOR(S): Oost, Thorsten; Lubisch, Wilfried; Wernet, Wolfgang; Hornberger, Wilfried; Unger, Liliane; Geneste, Herve; Netz, Astrid
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 135pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063123	A1	20070607	WO 2006-EP69180	20061201

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
 KP, KR, KZ, LA, LC, LK, LS, LT, LU, LV, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:


DE 2005-102005059484A 20051202

US 2005-742065P P 20051202

OTHER SOURCE(S): MARPAT 147:52806

ED Entered STN: 08 Jun 2007

GI



AB Title compds. I [A = substituted aromatic, heteroarom., etc.; B = substituted aromatic, heteroarom., etc.; R1 = H, halo, CN, etc.; R2 = H, alkyl, O-alkyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, claimed oxindole II was prepared from 3-bromo-4-methoxybenzaldehyde in 5 steps. In vasopressin receptor V_{lb} affinity assays, 235 examples of compds. I exhibited ki values ranging from <10-1000 nM.

IT 940276-41-5P 940276-43-7P 940276-45-9P
 940276-47-1P 940276-61-3P 940276-83-5P
 940276-91-5P 940276-95-9P 940276-99-3P
 940277-13-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylsulfonylindol-2-ones for the treatment of vasopressin dependent diseases)


RN 940276-41-5 HCPLUS

CN 2H-Indol-2-one, 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-[(2-oxazolylmethyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

10/574211

CRN 940276-40-4
CMF C29 H29 Cl N4 O6 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 940276-43-7 HCPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-[2-methoxy-5-(1-pyrrolidinylmethyl)phenyl]-3-[(2-oxazolylmethyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-42-6
CMF C31 H31 Cl N4 O6 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 940276-45-9 HCAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[2-methoxy-5-[(4-methyl-1-piperazinyl)methyl]phenyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(2-oxazolylmethyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-44-8
CMF C32 H34 Cl N5 O6 S


CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 940276-47-1 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[5-[(2-hydroxyethyl)amino]methyl]-
 2-methoxyphenyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(2-oxazolylmethyl)amino]-
 , 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-46-0
 CMF C29 H29 Cl N4 O7 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 940276-81-3 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[2-methoxy-5-[(4-methyl-1-piperazinyl)methyl]phenyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(1S)-1-(2-oxazolyl)ethyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-80-2
 CMF C33 H36 Cl N5 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 940276-83-5 HCPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[2-methoxy-5-[(methylamino)methyl]phenyl]-1-[(4-methoxyphenyl)sulfonyl]-3-[(2-oxazolymethyl)amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-82-4
CMF C28 H27 Cl N4 O6 S

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 940276-91-5 HCPLUS


CN 2H-Indol-2-one, 5-chloro-3-[5-[(dimethylamino)methyl]-2-methoxyphenyl]-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-[(1S)-1-(2-oxazolyl)ethyl]amino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-90-4

CMF C30 H31 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 940276-95-9 HCPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-[2-methoxy-5-[(propylamino)methyl]phenyl]-3-[(1S)-1-(2-oxazolyl)ethyl]amino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-94-8

CMF C31 H33 Cl N4 O6 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 940276-99-3 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-[2-methoxy-5-(1-piperazinylmethyl)phenyl]-3-[(1S)-1-(2-oxazolyl)ethyl]amino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 940276-98-2
CMF C32 H34 Cl N5 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 02




RN 940277-13-4 HCAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[5-[(2-hydroxyethyl)amino]methyl]-2-methoxyphenyl]-1-[4-(methoxyphenyl)sulfonyl]-3-[(1S)-1-(2-oxazolyl)ethyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

GM 1

CRN 940277-12-3
CMF C30 H31 C1 N4 Q7 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1


IT 940274-79-3P 940274-80-6P 940274-82-8P 940274-83-9P 940274-85-1P
 940274-87-3P 940274-89-5P 940274-91-9P 940274-93-1P 940274-95-3P
 940274-96-4P 940274-98-6P 940274-99-7P 940275-01-4P 940275-02-5P
 940275-04-7P 940275-06-9P 940275-08-1P 940275-10-5P 940275-12-7P
 940275-14-9P 940275-16-1P 940275-18-3P 940275-20-7P 940275-21-8P
 940275-22-9P 940275-23-0P 940275-25-2P 940275-27-4P 940275-29-6P
 940275-31-0P 940275-33-2P 940275-35-4P 940275-37-6P 940275-39-8P
 940275-41-2P 940275-43-4P 940275-45-6P 940275-46-7P 940275-48-9P
 940275-49-0P 940275-51-4P 940275-53-6P 940275-54-7P 940275-55-8P
 940275-56-9P 940275-57-0P 940275-58-1P 940275-59-2P 940275-60-5P
 940275-61-6P 940275-62-7P 940275-63-8P 940275-64-9P 940275-65-0P
 940275-66-1P 940275-67-2P 940275-68-3P 940275-69-4P 940275-70-7P
 940275-71-8P 940275-72-9P 940275-73-0P 940275-74-1P 940275-75-2P
 940275-76-3P 940275-77-4P 940275-78-5P 940275-79-6P 940275-81-0P
 940275-82-1P 940275-83-2P 940275-84-3P 940275-85-4P 940275-86-5P
 940275-87-6P 940275-88-7P 940275-89-8P 940275-90-1P 940275-91-2P
 940275-92-3P 940275-93-4P 940275-94-5P 940275-95-6P 940275-96-7P
 940275-97-8P 940275-98-9P 940275-99-0P 940276-00-6P 940276-01-7P
 940276-02-8P 940276-04-0P 940276-06-2P 940276-08-4P 940276-09-5P
 940276-10-8P 940276-12-0P 940276-14-2P 940276-16-4P 940276-18-6P
 940276-20-0P 940276-24-4P 940276-28-8P 940276-32-4P 940276-35-7P
 940276-37-9P 940276-39-1P 940276-41-5P 940276-43-7P
 940276-45-9P 940276-47-1P 940276-49-3P 940276-51-7P
 940276-53-9P 940276-55-1P 940276-57-3P 940276-59-5P 940276-61-9P
 940276-63-1P 940276-65-3P 940276-67-5P 940276-69-7P 940276-71-1P
 940276-73-3P 940276-75-5P 940276-77-7P 940276-79-9P
 940276-81-3P 940276-83-5P 940276-85-7P 940276-87-9P
 940276-89-1P 940276-91-5P 940276-95-9P
 940276-99-3P 940277-03-2P 940277-07-6P 940277-09-8P
 940277-11-2P 940277-13-4P 940277-15-6P 940277-16-7P
 940277-18-9P 940277-20-3P 940277-22-5P 940277-24-7P 940277-25-8P
 940277-26-9P 940277-28-1P 940277-30-5P 940277-32-7P 940277-34-9P
 940277-36-1P 940277-38-3P 940277-40-7P 940277-42-9P 940277-44-1P
 940277-46-3P 940277-48-5P 940277-50-9P 940277-52-1P 940277-54-3P
 940277-56-5P 940277-57-6P 940277-58-7P 940277-59-8P 940277-60-1P
 940277-62-3P 940277-63-4P 940277-64-5P 940277-65-6P 940277-66-7P
 940277-67-8P 940277-68-9P 940277-69-0P 940277-71-4P 940277-73-6P
 940277-74-7P 940277-75-8P 940277-76-9P 940277-77-0P 940277-78-1P
 940277-79-2P 940277-80-5P 940277-81-6P 940277-83-8P 940277-85-0P
 940277-87-2P 940277-88-3P 940277-89-4P 940277-90-7P 940277-91-8P
 940277-93-0P 940277-94-1P 940277-95-2P 940277-96-3P 940277-97-4P
 940277-99-6P 940278-01-3P 940278-03-5P 940278-05-7P 940278-06-8P
 940278-07-9P 940278-08-0P 940278-09-1P 940278-10-4P 940278-12-6P
 940278-14-8P 940278-16-0P 940278-18-2P 940278-20-6P 940278-22-8P
 940278-23-9P 940278-24-0P 940278-25-1P 940278-27-3P 940278-29-5P
 940278-30-8P 940278-31-9P 940278-33-1P 940278-35-3P 940278-37-5P
 940278-39-7P 940278-41-1P 940278-43-3P 940278-45-5P 940278-47-7P
 940278-49-9P 940278-51-3P 940278-53-5P 940278-55-7P 940278-57-9P
 940278-59-1P 940278-61-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylsulfonylindol-2-ones for the treatment of vasopressin dependent diseases)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 148:155904
 TITLE: 9-(Phenylsulfonyl)-9H-carbazol-2-ol
 AUTHOR(S): Kishbaugh, T. L. S.; Gribble, Gordon W.; Jasinski, Jerry P.
 CORPORATE SOURCE: Department of Chemistry, Dartmouth College, Hanover, NH, 03755-3564, USA
 SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2007), E63(5), o2472-o2473
 CODEN: ACSEBH; ISSN: 1600-5368
 URL: <http://journals.iucr.org/e/issues/2007/05/00/tk2149/tk2149.pdf>
 PUBLISHER: Blackwell Publishing Ltd.
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 148:155904
 ED Entered STN: 04 May 2007
 AB The crystal structure of 9-(phenylsulfonyl)-9H-carbazol-2-ol, C₁₈H₁₃NO₃S, confirms the structure of this compound formed from a Diels-Alder reaction between 3-nitro-1-(phenylsulfonyl)indole and 1-methoxy-3-(trimethylsiloxy)-1,3-butadiene (Danishefsky's diene). The angle between planes of the carbazole ring system and the phenylsulfonyl ring is 89.97(17)°. Crystallog. data are given.
 IT 1001206-50-3, 3-Nitro-1-(phenylsulfonyl)indole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Diels-Alder reaction with methoxy(trimethylsiloxy)butadiene)
 RN 1001206-50-3 HCAPLUS
 CN 1H-Indole, 2,3-dihydro-3-nitro-1-(phenylsulfonyl)- (CA INDEX NAME)




CC 75-8 (Crystallography and Liquid Crystals)
 Section cross-reference(s): 22, 27
 IT 1001206-50-3, 3-Nitro-1-(phenylsulfonyl)indole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Diels-Alder reaction with methoxy(trimethylsiloxy)butadiene)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:488174 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 148:155903
 TITLE: 4-Methoxy-4a-nitro-9-(phenylsulfonyl)-4,4a,9,9a-tetrahydro-1H-carbazol-2(3H)-one
 AUTHOR(S): Kishbaugh, T. L. S.; Gribble, Gordon W.; Jasinski, Jerry P.
 CORPORATE SOURCE: Department of Chemistry, Dartmouth College, Hanover, NH, 03755-3564, USA
 SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2007), E63(5), o2470-o2471
 CODEN: ACSEBH; ISSN: 1600-5368

URL: <http://journals.iucr.org/e/issues/2007/05/00/tk2148.pdf>



PUBLISHER: Blackwell Publishing Ltd.
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 148:155903
 ED Entered STN: 04 May 2007
 AB The crystal structure of 4-methoxy-4a-nitro-9-(phenylsulfonyl)-4,4a,9,9a-tetrahydro-1H-carbazol-2(3H)-one, C₁₉H₁₈N₂O₆S, confirms the structure of this novel Diels-Alder adduct formed from the reaction of 3-nitro-1-(phenylsulfonyl)indole and 1-methoxy-3-(trimethylsiloxy)-1,3-butadiene (Danishefsky's diene). The angle between the planes of the indoline ring system and the phenylsulfonyl ring is 69.9(4)°. Crystallog. data are given.
 IT 1001206-50-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Diels-Alder reaction with methoxy(trimethylsiloxy)butadiene)
 RN 1001206-50-3 HCPLUS
 CN 1H-Indole, 2,3-dihydro-3-nitro-1-(phenylsulfonyl)- (CA INDEX NAME)



CC 75-8 (Crystallography and Liquid Crystals)
 IT 1001206-50-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Diels-Alder reaction with methoxy(trimethylsiloxy)butadiene)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L26 ANSWER 5 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20061006561 HCPLUS Full-text
 DOCUMENT NUMBER: 145:377196
 TITLE: Preparation of 1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones and related compounds as vasopressin V_{1B} receptor modulators
 INVENTOR(S): Lubisch, Wilfried; Oost, Thorsten; Wernet, Wolfgang;
 Hornberger, Wilfried; Unger, Liliane; Geneste, Herve
 PATENT ASSIGNEE(S): Abbott G.M.B.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 80pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100080	A1	20060928	WO 2006-EP2683	20060323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 DE 102005014936 A1 20061214 DE 2005-102005014936 20050326
 CA 2601424 A1 20060928 CA 2006-2601424 20060323
 EP 1861390 A1 20071205 EP 2006-723671 20060323
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR
 MX 200711698 A 20080311 MX 2007-11698 20070921
 PRIORITY APPLN. INFO.: US 2005-664793P P 20050324
 DE 2005-102005014936A 20050326
 WO 2006-EP2683 W 20060323
 OTHER SOURCE(S): CASREACT 145:377196; MARPAT 145:377196
 ED Entered STN: 28 Sep 2006
 GI




AB Title compds. I [A = Ph, naphthyl; B = monocyclic or bicyclic aromatic ring with provisos; R1 = CN, R2 = H, alkyl, O-alkyl, etc.; R3 = W-X-Y-Z; W = alkylene, alkyl-O-alkyl, etc.; X = CO, SO2, C=NH, etc.; Y = pyrrolidinyl, piperidinyl, homopiperidinyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, phenylsulfonylindolone II was prepared from 5-iodoisatin in 5-steps. In vasopressin V1B receptor binding assays, 37-examples of compds. I exhibited Ki values <100 nM.


IT 910997-23-3P 910837-24-4P 910897-25-5P
 910897-26-6P 910837-27-7P 910897-28-8P
 910897-29-9P 910897-30-2P 910897-41-8P
 910897-45-9P 910897-46-0P 910897-47-1P
 910897-48-2P 910897-55-1P 910897-56-2P
 910897-57-3P 910897-58-4P 910897-59-5P
 910897-60-3P 910897-61-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylsulfonylindolones and related compds. as vasopressin


V1B receptor modulators)
 RN 910897-23-3 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)



RN 910897-24-4 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-25-5 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-26-6 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-difluorophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-27-7 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(4-cyanophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-28-8 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxy-4-methylphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-29-9 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-30-2 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-nitrophenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 910897-44-8 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-thiazolyl)- (CA INDEX NAME)




RN 910897-45-9 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(3-methyl-2-pyridinyl)- (CA INDEX NAME)




RN 910897-46-0 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)- (CA INDEX NAME)




RN 910897-47-1 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-pyrimidinyl)- (CA INDEX NAME)




RN 910897-48-2 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-pyrazinyl)- (CA INDEX NAME)




RN 910897-55-1 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-nitrophenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)- (CA INDEX NAME)




RN 910897-56-2 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-difluorophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)- (CA INDEX NAME)




RN 910897-57-3 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)- (CA INDEX NAME)




RN 910897-58-4 HCAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(4-chlorophenyl)sulfonyl]-5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)-(CA INDEX NAME)




RN 910897-59-5 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(4-cyanophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)-(CA INDEX NAME)




RN 910897-60-8 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)-(CA INDEX NAME)



RN 910897-61-9 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(5-cyano-2-pyridinyl)- (CA INDEX NAME)



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT	910897-14-2P	910897-15-3P	910897-16-4P	910897-17-5P	910897-18-6P
	910897-19-7P	910897-20-0P	910897-21-1P	910897-22-2P	
	910897-23-3P	910897-24-4P	910897-25-5P		
	910897-26-6P	910897-27-7P	910897-28-8P		
	910897-29-9P	910897-30-2P	910897-31-3P	910897-32-4P	
	910897-33-5P	910897-34-6P	910897-35-7P	910897-36-8P	910897-37-9P
	910897-38-0P	910897-39-1P	910897-40-4P	910897-41-5P	910897-42-6P
	910897-43-7P	910897-44-8P	910897-45-9P		
	910897-46-0P	910897-47-1P	910897-48-2P		
	910897-49-3P	910897-50-6P	910897-51-7P	910897-52-8P	910897-53-9P
	910897-54-0P	910897-55-1P	910897-56-2P		
	910897-57-3P	910897-58-4P	910897-59-5P		
	910897-60-8P	910897-61-9P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylsulfonylindolones and related compds. as vasopressin V1B receptor modulators)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 6 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:765145 HCPLUS Full-text

DOCUMENT NUMBER: 145:210877

TITLE: Preparation of 1,3-dihydro-2H-indol-2-one compounds

and pyrrolidin-2-one compound fused with aromatic heterocycle as antagonists of arginine-vasopressin V_{1b} receptor

INVENTOR(S): Sekiguchi, Yoshinori; Kuwada, Takeshi; Hayashi, Masato; Nozawa, Dai; Amada, Yuri; Shibata, Tsuyoshi; Yamamoto, Shuji; Ohta, Hiroshi; Okubo, Taketoshi; Koami, Takeshi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 674pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006080574	A1	20060803	WO 2006-JP301913	20060130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2005-21010 A 20050128

OTHER SOURCE(S): MARPAT 145:210877

ED Entered STN: 03 Aug 2006

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; ring A = each (un)substituted C₆-14 aryl or aromatic heterocycl; P = a single bond, C₁-5 alkylene; Q = each (un)substituted C₆-14 aryl or aromatic heterocycl, Q1; RD and RE at 2 and 3 or 3 and 4 positions together form (un)substituted C₁-3 alkylenedioxy, (CH₂)_m-O, N-(un)substituted (CH₂)_m-NH or NH-(CH₂)_m, (CH₂)_m-S, O-(CH₂)_m-S, or S-(CH₂)_m-S (*m* = 2-4); R5 = Q2, Q3, etc.; R6 = H, halo, (un)substituted HO; R7 = H, halo, (un)substituted SH; or R6 and R7 together represent oxo; R9 = each (un)substituted OH, SH or NH₂; R33 = H, (un)substituted C₁-5 alkyl, C₃-8 cycloalkyl, C₁-5 alkoxy carbonyl, C₆-14 aryl, heterocycl; RA, RB, RC = H, halo, NO₂, NH₂, hydroxyamino, C₁-5 alkyl, C₁-5 alkoxy, C₁-5 alkylthio, etc.] or pharmacol. acceptable salts thereof are prepared. These compds. are highly selectively antagonistic to arginine-vasopressin V_{1b} receptor over arginine-vasopressin V_{1a} receptor and arginine-vasopressin V₂ receptor, have high metabolic stabilities and show favorable migration into the brain and high concns. in the plasma. They provide drugs which are efficacious against pathol. conditions relating to arginine-vasopressin V_{1b} receptor. More particularly speaking, they provide drugs which have a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury,

inflammation, immune diseases, alopecia and so on. Thus, reductive amination of (4R)-1-((3R)-5-Chloro-3-[2-methoxy-5-(2-oxoethyl)phenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-L-prolinamide with piperidine using sodium triacetoxypyroborohydride in the presence of acetic acid din a mixture of THF and CHCl₃ gave (+)-(4R)-1-[5-Chloro-3-[5-[2-(dimethylamino)ethyl]-2-methoxyphenyl]-1-[(4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-N,N-dimethyl-L-prolinamide (II). II inhibited the binding of [³H](Arg8)vasopressin to human arginine vasopressin V_{1b}, V_{1a}, and V₂ receptor with IC₅₀ of 0.32, 102, and 5,050, nM, resp.

IT 905084-50-6P 905084-54-0P 905084-70-0P

905084-77-7P 905084-85-7P 905084-92-6P


905087-68-5P 905099-46-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused with aromatic heterocycle as selective antagonists of arginine vasopressin V_{1b} receptor)


RN 905084-50-6 HCPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-1,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]- (CA INDEX NAME)




RN 905084-54-0 HCPLUS

CN Carbamic acid, [5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 905084-70-0 HCPLUS


CN Glycine, N-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 905084-77-7 HCPLUS
 CN Glycine, N-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 905084-85-7 HCPLUS
 CN β -Alanine, N-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 905084-92-6 HCPLUS
 CN β -Alanine, N-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 905087-68-5 HCPLUS

CN 1H-Imidazole-1-carboxylic acid, 4-[(2S)-2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino)-3-(dimethylamino)-3-oxopropyl]-, 1,1-dimethylethyl ester
(CA INDEX NAME)

Absolute stereochemistry.




RN 905089-46-5 HCPLUS

CN Benzenepropanamide, α -[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl)amino]-N,N-dimethyl-4-(phenylmethoxy)-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




IT 905084-46-0P 905084-66-4P 905084-81-3P
 905084-95-0P 905085-12-3P 905085-31-6P
 905085-46-3P 905085-64-5P 905085-82-7P
 905085-96-1P 905086-01-3P 905086-18-2P
 905086-32-0P 905086-50-2P 905086-66-0P
 905086-92-0P 905086-96-6P 905087-07-2P
 905087-17-4P 905087-28-7P 905087-37-8P
 905087-48-1P 905087-71-0P 305087-88-9P
 905088-31-5P 905088-52-0P 905088-72-4P
 905088-94-0P 905089-22-7P 905089-50-1P
 905105-35-3P 905105-58-0P 905105-79-5P
 905105-95-5P 905106-19-6P 905106-39-0P
 905106-59-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused with aromatic heterocycle as selective antagonists of arginine vasopressin V_{1b} receptor)


RN 905084-46-0 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-(CA INDEX NAME)




RN 905084-66-4 HCPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-3-[(2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl)amino]-(CA INDEX NAME)



RN 905084-81-3 HCPLUS


CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-3-[(3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl)amino]- (CA INDEX NAME)



RN 905084-96-0 HCPLUS

CN Pentanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl)amino]-N,N,4-trimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905085-12-3 HCAPLUS


CN Propanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905085-31-6 HCAPLUS


CN Acetamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (CA INDEX NAME)



RN 905085-46-3 HCAPLUS

CN Pentanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N,3-trimethyl-, (2S,3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905085-64-5 HCPLUS

CN Benzenepropanamide, α -[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905085-82-7 HCPLUS

CN Propanamide, 2-[($(3R)$ -5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-3-hydroxy-N,N-dimethyl-, ($(2S)$)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905085-86-1 HCAPLUS

CN Propanamide, 2-[(3S)-5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-3-hydroxy-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905086-01-3 HCAPLUS

CN Butanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino)-N,N-dimethyl-4-(methylthio)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905086-18-2 HCPLUS

CN Butanediamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N1,N1-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905086-32-0 HCPLUS


CN Pentanediamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N1,N1-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905086-50-2 HCAPLUS
 CN Butanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N1,N1,N4,N4-tetramethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905086-66-0 HCAPLUS
 CN Pentanediamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N1,N1,N5,N5-tetramethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905086-82-0 HCPLUS

CN Propanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl)methylamino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905086-96-6 HCPLUS

CN 1H-Indole-3-propanamide, α -[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl)amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905087-07-2 HCPLUS

CN 4-Thiazolepropanamide, α -[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 905087-17-4 HCPLUS

CN Butanamide, 2-[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905087-28-7 HCAPLUS
 CN Cyclohexanecarboxamide, 1-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[{[4-methoxy-2-(trifluoromethoxy)phenyl}sulfonyl]-2-oxo-1H-indol-3-yl]amino}-N,N-dimethyl- (CA INDEX NAME)




RN 905087-37-8 HCAPLUS
 CN Cyclopentanecarboxamide, 1-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[{[4-methoxy-2-(trifluoromethoxy)phenyl}sulfonyl]-2-oxo-1H-indol-3-yl]amino}-N,N-dimethyl- (CA INDEX NAME)



RN 905087-48-1 HCAPLUS

CN 1H-Imidazole-5-propanamide, α -{[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905087-71-0 HCAPLUS

CN Carbamic acid, [(5S)-5-[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-6-(dimethylamino)-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 905087-88-9 HCAPLUS

CN Propanamide, 2-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl}(2-hydroxyethyl)amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905088-31-5 HCPLUS

CN Butanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N,3-trimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905088-52-0 HCPLUS

CN 4-Pyridinepropanamide, α -[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905088-72-4 HCPLUS

CN 2-Pyridinepropanamide, α -[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905088-94-0 HCPLUS

CN 3-Pyridinepropanamide, α -[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 905089-22-7 HCPLUS

CN Benzenepropanamide, α -[[5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl]amino]-4-hydroxy-N,N-dimethyl-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 905089-50-1 HCPLUS

CN Benzeneacetamide, α -[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905105-35-3 HCPLUS


CN Propanamide, 2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl](2-pyridinylmethyl)amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 905105-58-0 HCPLUS
 CN Propanamide, 2-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N-methoxy-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905105-79-5 HCPLUS
 CN Propanamide, 2-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N,2-trimethyl- (CA INDEX NAME)




RN 905105-95-5 HCPLUS
 CN Cyclohexaneacetamide, α -[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl}amino]-N,N-dimethyl-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 905106-19-6 HCPLUS
 CN Propanamide, 2-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl}amino]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 905106-39-0 HCPLUS
 CN Propanamide, 2-[{5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-1H-indol-3-yl}(phenylmethyl)amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 905106-59-4 HCPLUS

CN Hexanamide, 6-amino-2-[(5-chloro-2,3-dihydro-3-(2-methoxyphenyl)-1-[(4-methoxy-2-(trifluoromethoxy)phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]amino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 28, 34

IT 581-45-3P, 4-(Piperidin-4-yl)pyridine 774-82-3P 17100-64-0P
 19056-41-8P, 3-Bromo-4-methoxyaniline 30992-29-1P, N-(tert-Butoxycarbonyl)-2-methylalanine 32229-19-9P, 2-Bromo-4-isopropyl-1-methoxybenzene 32326-40-2P 34306-42-8P, (2S)-2-[(tert-Butoxycarbonyl)amino]butanoic acid 35264-09-6P, 1-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid 38493-59-3P, (3-Bromo-4-methoxyphenyl)methanol 41280-65-3P 42718-51-4P
 42718-52-5P 42771-30-2P, 2,3,4-Trimethoxybenzenesulfonyl chloride 62147-27-7P 70548-79-7P 72080-89-8P 72287-76-4P 74844-91-0P, 1-tert-Butyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate 74844-93-2P 78800-68-7P 83181-57-1P 83548-46-3P 83548-49-6P
 85477-01-6P, 2,4,5-Trimethoxybenzenesulfonyl chloride 87694-49-3P
 89813-47-8P 90642-46-9P 100125-96-0P 102195-80-2P, 1-tert-Butyl 2-methyl (2S)-4-oxopyrrolidine-1,2-dicarboxylate 102236-13-5P
 115951-16-1P, 1-[(tert-Butoxycarbonyl)amino]cyclohexanecarboxylic acid

125218-78-2P	126937-41-5P, 1-[(Benzylxyloxy)carbonyl]-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid	127423-55-6P	128636-85-1P
128636-99-7P	131792-55-7P	142738-94-1P	149142-67-6P
153460-90-3P	153461-00-8P	153548-49-3P	154462-98-3P
186431-37-8P	186431-79-8P	191602-60-5P, 4-(3-Bromo-4-methoxyphenyl)pyridine	192821-24-2P
203866-13-1P	203866-15-3P	203866-16-4P	203866-17-5P
204398-85-6P	214784-83-5P	223418-72-2P, 2-(3-Bromo-4-methoxyphenyl)-1,3-dioxolane	241825-30-9P
383424-83-7P	383425-10-3P	394734-93-1P, Benzyl [(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]carbamate	444341-95-1P
492430-23-6P, 5-Chloro-3-(2-fluorophenyl)-3-hydroxy-1,3-dihydro-2H-indol-2-one	556834-89-0P	556834-90-3P	682353-53-3P
807322-36-7P	807322-38-9P	847866-18-6P	847866-20-0P, tert-Butyl (2S,4R)-2-[(dimethylamino)carbonyl]-4-fluoropyrrolidine-1-carboxylate
847866-21-1P	847866-22-2P	847866-23-3P	847866-24-4P
847866-27-7P	847866-28-8P	847866-29-9P	847866-31-3P
847866-33-5P	847866-34-6P	847866-35-7P	847866-36-8P
847866-44-8P, tert-Butyl (2S,4S)-2-[(azetidin-1-yl)carbonyl]-4-hydroxypyrrolidine-1-carboxylate		847866-45-9P	847866-47-1P
847866-51-7P	847866-53-9P	847866-55-1P	847866-57-3P
847866-63-1P	847866-65-3P	847866-66-4P	847866-70-0P
847866-72-2P	847866-73-3P	847866-74-4P	847866-75-5P
847866-79-9P	847866-81-3P	847866-84-6P	847866-86-8P
847866-90-4P	847866-91-5P	898874-47-0P	905077-05-6P
905077-14-7P	905077-18-1P	905077-49-8P	905077-87-4P
905078-13-9P	905078-17-3P	905078-54-8P	905078-62-8P
905078-74-2P	905078-78-6P	905078-82-2P	905079-47-2P
905079-59-6P	905079-89-2P	905079-94-9P	905080-00-4P
905080-96-8P	905081-72-3P	905081-76-7P	905082-06-6P
905082-14-6P	905082-18-0P	905082-26-0P	905082-30-6P
905082-48-6P	905082-53-3P	905082-92-0P	905082-99-7P
905083-07-0P	905083-15-0P	905083-22-9P	905083-38-7P
905083-57-0P	905083-68-3P	905083-80-9P	905083-98-9P
905084-14-2P	905084-18-6P	905084-26-6P	905084-38-0P
905084-50-6P	905084-54-0P	905084-62-0P	
905084-70-0P	905084-77-7P	905084-85-7P	
905084-92-6P	905085-04-3P	905085-08-7P	905085-23-6P
905085-27-0P	905085-38-3P	905085-42-9P	905085-56-5P
905085-74-7P	905085-78-1P	905085-93-0P	905085-97-4P
905086-12-6P	905086-15-9P	905086-26-2P	905086-29-5P
905086-41-1P	905086-44-4P	905086-47-7P	905086-53-5P
905086-60-4P	905086-63-7P	905086-69-3P	905086-73-9P
905086-79-5P	905086-87-5P	905086-90-0P	905086-93-3P
905087-03-8P	905087-05-0P	905087-10-7P	905087-12-9P
905087-19-6P	905087-22-1P	905087-24-3P	905087-26-5P
905087-33-4P	905087-35-6P	905087-39-0P	905087-42-5P
905087-51-6P	905087-56-1P	905087-59-4P	905087-62-9P
905087-68-5P	905087-80-1P	905087-84-5P	905087-95-8P
905087-99-2P	905088-03-1P	905088-07-5P	
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)			
(intermediate; preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused with aromatic heterocycle as selective antagonists of arginine vasopressin Vlb receptor)			
IT	905088-15-5P	905088-23-5P	905088-27-9P
	905088-56-4P	905088-64-4P	905088-68-8P
	905088-90-6P	905088-99-5P	905089-12-5P
	905089-34-1P	905089-38-5P	905089-42-1P
			905089-46-5P

905089-60-3P	905089-64-7P	905089-75-0P	905089-79-4P	905089-91-0P
905089-95-4P	905090-03-1P	905090-15-5P	905090-19-9P	905090-32-6P
905090-36-0P	905090-48-4P	905090-52-0P	905090-60-0P	905090-64-4P
905090-67-7P	905090-76-8P	905090-79-1P	905090-86-0P	905090-88-2P
905090-97-3P	905091-04-5P	905091-09-0P	905091-12-5P	905091-25-0P
905091-28-3P	905091-32-9P	905091-34-1P	905091-39-6P	905091-41-0P
905091-43-2P	905091-47-6P	905091-49-8P	905091-51-2P	905091-55-6P
905091-57-8P	905091-59-0P	905091-64-7P	905091-66-9P	905091-71-6P
905091-73-8P	905091-81-8P	905091-88-5P	905091-94-3P	905091-97-6P
905092-00-4P	905092-03-7P	905092-18-4P	905092-32-2P	905092-35-5P
905092-44-6P	905092-53-7P	905092-58-2P	905092-61-7P	905092-64-0P
905092-67-3P	905092-70-8P	905092-86-6P	905092-90-2P	905092-97-9P
905093-01-8P	905093-13-2P	905093-21-2P	905093-25-6P	905093-33-6P
905093-37-0P	905093-53-0P	905093-57-4P	905093-61-0P	905093-85-8P
905093-89-2P	905094-05-5P	905094-16-8P	905094-20-4P	905094-31-7P
905094-41-9P	905094-45-3P	905094-58-8P	905094-62-4P	905094-70-4P
905094-74-8P	905094-86-2P	905094-90-8P	905094-94-2P	905095-02-5P
905095-07-0P	905095-11-6P	905095-15-0P	905095-30-9P	905095-35-4P
905095-38-7P	905095-49-0P	905095-56-9P	905095-61-6P	905095-65-0P
905095-77-4P	905095-84-3P	905095-88-7P	905096-04-0P	905096-09-5P
905096-13-1P	905096-17-5P	905096-33-5P	905096-38-0P	905096-42-6P
905096-46-0P	905096-61-9P	905096-90-4P	905096-94-8P	905097-13-4P
905097-31-6P	905097-35-0P	905097-58-7P	905097-62-3P	905097-66-7P
905097-73-6P	905097-77-0P	905097-85-0P	905097-91-8P	905097-94-1P
905098-45-5P	905098-49-9P	905098-53-5P	905098-69-3P	905098-73-9P
905098-77-3P	905098-81-9P	905099-25-4P	905099-28-7P	905099-34-5P
905099-39-0P	905099-43-6P	905099-47-0P	905099-51-6P	905099-62-9P
905099-65-2P	905099-68-5P	905099-75-4P	905099-82-3P	905099-86-7P
905099-89-0P	905099-93-6P	905100-08-5P	905100-12-1P	905100-27-8P
905100-31-4P	905100-39-2P	905100-43-8P	905100-45-0P	905100-57-4P
905100-60-9P	905101-08-8P	905101-12-4P	905101-16-8P	905101-20-4P
905101-24-8P	905101-28-2P	905101-85-1P	905101-88-4P	905101-91-9P
905101-94-2P	905101-98-6P	905102-06-9P	905102-49-0P	905102-65-0P
905102-69-4P	905102-73-0P	905102-84-3P	905102-88-7P	905102-92-3P
905103-04-0P	905103-07-3P	905103-10-8P	905103-13-1P	905103-22-2P
905103-26-6P	905103-38-0P	905103-42-6P	905103-50-6P	905103-54-0P
905103-58-4P	905103-73-3P	905103-77-7P	905103-81-3P	905103-85-7P
905103-97-1P	905104-01-0P	905104-11-2P	905104-14-5P	905104-25-8P
905104-28-1P	905104-37-2P	905104-40-7P	905104-43-0P	905104-55-4P
905104-59-8P	905104-67-8P	905104-71-4P	905104-75-8P	905104-83-8P
905104-87-2P	905104-91-8P	905104-99-6P	905105-03-5P	905105-07-9P
905105-19-3P	905105-23-9P	905105-27-3P	905105-39-7P	905105-46-6P
905105-50-2P	905105-54-6P	905105-68-2P	905105-71-7P	905105-75-1P
905105-83-1P	905105-87-5P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused with aromatic heterocycle as selective antagonists of arginine vasopressin V1b receptor)

IT	905077-22-7P	905077-30-7P	905077-34-1P	905077-38-5P	905077-42-1P
	905077-53-4P	905077-80-7P	905077-95-4P	905077-99-8P	905078-03-7P
	905078-21-9P	905078-44-6P	905078-58-2P	905078-87-7P	905079-11-0P
	905079-33-6P	905079-43-8P	905079-63-2P	905080-09-3P	905080-22-0P
	905080-27-5P	905080-38-8P	905080-42-4P	905080-55-9P	905080-59-3P
	905080-69-5P	905080-85-5P	905081-00-7P	905081-04-1P	905081-16-5P
	905081-21-2P	905081-38-1P	905081-52-9P	905081-68-7P	905081-80-3P
	905081-88-1P	905081-92-7P	905081-96-1P	905082-22-6P	905082-38-4P
	905082-58-8P	905082-62-4P	905082-66-8P	905082-73-7P	905082-77-1P
	905082-81-7P	905082-88-4P	905083-11-6P	905083-26-3P	905083-30-9P
	905083-34-3P	905083-45-6P	905083-53-6P	905083-61-6P	905083-65-0P

905083-72-9P	905083-76-3P	905083-90-1P	905083-94-5P	905084-02-8P
905084-06-2P	905084-22-2P	905084-30-2P	905084-34-6P	905084-42-6P
905084-46-0P	905084-58-4P	905084-66-4P		
905084-81-3P	905084-96-0P	905085-12-3P		
905085-31-6P	905085-46-3P	905085-64-5P		
905085-92-7P	905085-86-1P	905086-01-3P		
905086-18-2P	905086-33-0P	905086-50-2P		
905086-66-0P	905086-82-0P	905086-96-6P		
905087-07-2P	905087-17-4P	905087-28-7P		
905087-37-8P	905087-48-1P	905087-71-0P		
905087-88-9P	905088-11-1P	905088-19-9P	905088-31-%E	
905088-52-0P	905088-72-4P	905088-94-0P		
905089-22-7P	905099-56-1P	905089-68-1P	905089-83-0P	
905089-87-4P	905089-99-8P	905090-07-5P	905090-11-1P	905090-23-5P
905090-28-0P	905090-40-6P	905090-44-0P	905090-56-4P	905090-70-2P
905090-73-5P	905090-82-6P	905090-91-7P	905090-93-9P	905090-99-5P
905091-01-2P	905091-06-7P	905091-17-0P	905091-22-7P	905091-30-7P
905091-37-4P	905091-45-4P	905091-53-4P	905091-62-5P	905091-67-0P
905091-69-2P	905091-75-0P	905091-78-3P	905091-91-0P	905092-06-0P
905092-09-3P	905092-12-8P	905092-15-1P	905092-23-1P	905092-26-4P
905092-29-7P	905092-38-8P	905092-41-3P	905092-47-9P	905092-50-4P
905092-74-2P	905092-78-6P	905092-82-2P	905093-05-2P	905093-09-6P
905093-17-6P	905093-29-0P	905093-41-6P	905093-45-0P	905093-49-4P
905093-65-4P	905093-69-8P	905093-73-4P	905093-77-8P	905093-81-4P
905093-93-8P	905093-97-2P	905094-01-1P	905094-12-4P	905094-24-8P
905094-27-1P	905094-37-3P	905094-54-4P	905094-66-8P	905094-78-2P
905094-98-6P	905095-45-6P	905095-69-4P	905095-73-0P	905095-92-3P
905095-96-7P	905096-00-6P	905096-21-1P	905096-25-5P	905096-29-9P
905096-50-6P	905096-54-0P	905096-65-3P	905096-68-6P	905096-71-1P
905096-74-4P	905096-77-7P	905096-81-3P	905096-97-1P	905097-01-0P
905097-05-4P	905097-09-8P	905097-20-3P	905097-24-7P	905097-28-1P
905097-42-9P	905097-46-3P	905097-50-9P	905097-54-3P	905097-81-6P
905098-00-2P	905098-03-5P	905098-10-4P	905098-17-1P	905098-21-7P
905098-25-1P	905098-29-5P	905098-33-1P	905098-41-1P	905098-57-9P
905098-61-5P	905098-65-9P	905098-85-3P	905098-89-7P	905098-93-3P
905098-97-7P	905099-01-6P	905099-05-0P	905099-09-4P	905099-13-0P
905099-17-4P	905099-20-9P	905099-31-2P	905099-55-0P	905099-72-1P
905099-97-0P	905100-01-8P	905100-16-5P	905100-20-1P	905100-48-3P
905100-51-8P	905100-54-1P	905100-65-4P	905100-69-8P	905100-73-4P
905100-77-8P	905100-81-4P	905100-84-7P	905100-88-1P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused

with

aromatic heterocycle as selective antagonists of arginine vasopressin V_{1b} receptor)

IT	905100-92-7P	905100-96-1P	905101-00-0P	905101-04-4P	905101-35-1P
	905101-39-5P	905101-43-1P	905101-47-5P	905101-51-1P	905101-55-5P
	905101-59-9P	905101-63-5P	905101-67-9P	905101-71-5P	905101-74-8P
	905101-76-0P	905102-02-5P	905102-10-5P	905102-14-9P	905102-18-3P
	905102-22-9P	905102-26-3P	905102-30-9P	905102-33-2P	905102-37-6P
	905102-41-2P	905102-45-6P	905102-53-6P	905102-57-0P	905102-61-6P
	905102-77-4P	905102-96-7P	905103-16-4P	905103-19-7P	905103-30-2P
	905103-34-6P	905103-46-0P	905103-62-0P	905103-66-4P	905103-89-1P
	905103-93-7P	905104-05-4P	905104-17-8P	905104-22-5P	905104-31-6P
	905104-34-9P	905104-47-4P	905104-51-0P	905104-63-4P	905104-79-2P
	905104-95-2P	905105-11-5P	905105-15-9P	905105-31-9P	
	905105-35-3P	905105-58-0P	905105-65-9P		
	905105-79-5P	905105-95-5P	905106-19-6P		

905106-39-0P 905106-59-4P 905106-63-0P 905106-71-0P
 905106-75-4P 905106-79-8P 905106-83-4P 905106-87-8P 905106-91-4P
 905106-95-8P 905107-10-0P 905107-19-9P 905107-29-1P 905107-44-0P
 905107-56-4P 905107-60-0P 905289-70-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,3-dihydro-2H-indol-2-ones and pyrrolidin-2-ones fused with

aromatic heterocycle as selective antagonists of arginine vasopressin V_{1b} receptor)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:681060 HCPLUS Full-text

DOCUMENT NUMBER: 145:145538

TITLE: Preparation of phenylsulfonylindolones and related compounds for the treatment of vasopressin or oxytocin dependent diseases

INVENTOR(S): Lubisch, Wilfried; Oost, Thorsten; Wernet, Wolfgang; Unger, Liliiane; Hornberger, Wilfried; Geneste, Herve

PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072458	A2	20060713	WO 2005-EP14150	20051230
WO 2006072458	A3	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2593044	A1	20060713	CA 2005-2593044	20051230
EP 1831197	A2	20070912	EP 2005-820446	20051230
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
PRIORITY APPLN. INFO.:			DE 2004-102004063843A 20041231	
			DE 2005-102005014105A 20050318	
			US 2005-663349P P 20050318	
			WO 2005-EP14150 W 20051230	

OTHER SOURCE(S): MARPAT 145:145538

ED Entered STN: 14 Jul 2006

GI



AB Title compds. I [A = aryl with provisos; B = aromatic ring with provisos; X = H, halo, CN, etc.; Y = N(R1)C(R2R3R4); R1 = H, alkyl, cycloalkyl; R2 = H, alkyl, cycloalkyl; R3 = H, alkyl, cycloalkyl; R4 = H, CO2H, CO2-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, phenylsulfonylindolone II was prepared from 5-iodoisatin in 4-steps. Compds. I claimed to be useful as vasopressin V1B receptor inhibitors (no data provided).

IT 898872-37-2P 898872-54-3P 898872-72-5P

898872-78-1P 898872-86-1P 898872-93-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of phenylsulfonylindolones and related compds. for treatment of

vasopressin or oxytocin dependent diseases)

RN 898872-37-2 HCPLUS

CN Propanamide, 2-[(3S)-5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]methylamino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 898872-54-3 HCPLUS

CN Propanamide, 2-[(3R)-5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]methylamino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 898872-72-5 HCPLUS

CN Propanamide, 2-[{1-[(4-chlorophenyl)sulfonyl]-5-cyano-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]methylamino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 898872-78-1 HCPLUS

CN Propanamide, 2-[{1-[(5-cyano-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl)sulfonyl]phenyl}sulfonyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 898872-86-1 HCPLUS

CN Propanamide, 2-[{1-[(5-cyano-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl)sulfonyl]phenyl}sulfonyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 898872-93-0 HCPLUS

CN Propanamide, 2-[{5-cyano-2,3-dihydro-3-(2-methoxyphenyl)-1-[{(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl}methylamino]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

IT 898872-09-8P 898872-15-6P 898872-21-4P 898872-26-9P 898872-32-7P
 898872-37-2P 898872-43-0P 898872-48-5P 898872-54-3P
 898872-60-1P 898872-66-7P 898872-72-5P 898872-78-1P
 898872-86-1P 898872-93-0P 898873-01-3P 898873-07-9P
 898873-14-8P 898873-20-6P 898873-27-3P 898873-33-1P 898873-38-6P
 898873-44-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

of (preparation of phenylsulfonylindolones and related compds. for treatment
 vasopressin or oxytocin dependent diseases)

L26 ANSWER 8 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:54890 HCPLUS Full-text

DOCUMENT NUMBER: 144:150235

TITLE: Preparation of 1,3-dihydro-1-(phenylsulfonyl)-2H-indol-2-ones and related compounds as vasopressin V1B receptor modulators

INVENTOR(S): Lubisch, Wilfried; Oost, Thorsten; Wernet, Wolfgang;
 Unger, Liliiane; Hornberger, Wilfried; Geneste, Herve


PATENT ASSIGNEE(S): Abbott GmbH & Co.Kg, Germany
 SOURCE: PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005609	A2	20060119	WO 2005-EP7631	20050713
WO 2006005609	A3	20060316		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004033834	A1	20060202	DE 2004-102004033834	20040713
AU 2005261867	A1	20060119	AU 2005-261867	20050713
CA 2573404	A1	20060119	CA 2005-2573404	20050713
EP 1773814	A2	20070418	EP 2005-786049	20050713
EP 1773814	B1	20071107		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR CN 101018778	A	20070815	CN 2005-80030708	20050713
AT 377595	T	20071115	AT 2005-786049	20050713
JP 2008506647	T	20080306	JP 2007-520751	20050713
ES 2297755	T3	20080501	ES 2005-786049	20050713
BR 2005013281	A	20080506	BR 2005-13281	20050713
MX 200700505	A	20070625	MX 2007-505	20070112
IN 2007MN00199	A	20070824	IN 2007-MN199	20070208
KR 2007051273	A	20070517	KR 2007-703328	20070212
PRIORITY APPLN. INFO.:			DE 2004-102004033834A	20040713
			US 2004-587407P	P 20040713
			WO 2005-EP7631	W 20050713

OTHER SOURCE(S): MARPAT 144:150235

ED Entered STN: 20 Jan 2006

GI



AB Title compds. I [A = (un)substituted aryl; B = (un)substituted aromatic, etc.; R1 = H, alkyl, OH, etc.; R2 = H, alkyl, O-alkyl, etc.; R3 = -Z-Y-X-W; W = alkylene, alkylene-O-alkylene, etc.; X = CO, SO₂, C=NH, etc.; Y = pyrrolidinyl, pyridinyl, azepanyl, etc.] and their pharmaceutically acceptable salts were prepared. For example, phenylsulfonylindolone II was prepared from 5-chloroisatin in 4-steps. In vasopressin V1B receptor binding assays, 9-examples of compds. I exhibited Ki values <100 nM.


IT
 873954-66-3P 873954-09-7P 873954-26-8P
 873954-27-9P 873954-32-6P 873954-23-7P
 873954-34-8P 873954-35-9P 873954-36-0P
 873954-42-8P 873954-43-9P 873954-62-2P
 873954-63-3P 873954-64-4P 873954-65-5P
 873954-66-6P 873954-79-1P 873954-80-4P
 873954-81-5P 873954-82-6P 873954-84-8P
 873954-85-9P 873954-87-1P 873954-88-2P
 873954-90-6P 873954-95-1P 873954-99-5P
 873955-00-1P 873955-01-2P 873955-02-3P
 873955-05-6P 873955-11-4P 873955-12-5P
 873955-13-6P 873955-14-7P 873955-15-8P
 873955-16-9P 873955-25-0P 873955-26-1P
 873955-27-2P 873955-41-0P 873955-42-1P
 873955-43-2P 873955-44-3P 873955-45-4P
 873955-46-5P 873955-47-6P 873955-60-3P
 873955-61-4P 873955-62-5P 873955-63-6P
 873955-64-7P 873955-65-8P 873955-66-9P
 873955-67-0P 873955-68-1P 873955-70-5P
 873956-46-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylsulfonylindolones and related compds. for the treatment of vasopressin or oxytocin dependent diseases)

RN 873953-66-3 HCAPLUS


CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 873954-09-7 HCAPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxy-4-methylphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 873954-26-8 HCAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 873954-27-9 HCAPLUS


CN 1-Piperazinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 873954-32-6 HCPLUS


CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 873954-33-7 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873954-34-8 HCAPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-[2,4,6-trimethylphenyl)sulfonyl]-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl


RN 873954-35-9 HCAPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(4-cyanophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 873954-36-0 HCAPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 873954-42-8 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-
 (CA INDEX NAME)




RN 873954-43-9 HCPLUS
 CN 1-Piperazinecarboxamide, N-[2,3-dihydro-5-methoxy-3-[2-(2-methoxyethyl)phenyl]-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 873954-62-2 HCAPLUS

CN 1-Piperazinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-(CA INDEX NAME)




RN 873954-63-3 HCAPLUS

CN 1-Piperazinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-(CA INDEX NAME)




RN 873954-64-4 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873954-65-5 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873954-66-6 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-chloro-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 873954-79-1 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873954-80-4 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 873954-81-5 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-


methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-,
hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 873954-82-6 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)




RN 873954-84-8 HCPLUS

CN 1-Piperazinecarboxamide, N-[1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-
(CA INDEX NAME)




RN 873954-85-9 HCAPLUS
 CN 1-Piperazinecarboxamide, N-[3-(2-ethoxyphenyl)-5-fluoro-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl


RN 873954-87-1 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (CA INDEX NAME)




RN 873954-88-2 HCAPLUS
 CN 1-Piperazinecarboxamide, N-[3-(2-ethoxyphenyl)-5-fluoro-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-(CA INDEX NAME)




RN 873954-90-6 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-(CA INDEX NAME)



RN 873954-95-1 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-(CA INDEX NAME)




RN 873954-99-5 HCPLUS
 CN 1-Piperidinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873955-00-1 HCPLUS
 CN 1-Piperidinecarboxamide, N-[1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873955-01-2 HCPLUS
 CN 1-Piperidinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873955-02-3 HCPLUS
 CN 1-Piperidinecarboxamide, N-[3-(2-ethoxyphenyl)-2,3-dihydro-5-methoxy-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 873955-05-6 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-methyl-1-piperazinyl)-, (CA INDEX NAME)




RN 873955-11-4 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 873955-12-5 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-13-6 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-14-7 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 873955-15-8 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-16-9 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl


RN 873955-25-0 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-(CA INDEX NAME)




RN 873955-26-1 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-(CA INDEX NAME)




RN 873955-27-2 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-difluorophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 873955-41-0 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-(phenylsulfonyl)-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-42-1 HCPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-43-2 HCPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-44-3 HCPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-45-4 HCPLUS


CN 1-Piperidinecarboxamide, N-[5-cyano-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)



RN 873955-46-5 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-3-{2-(1-methylethoxy)phenyl}-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-47-6 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(4-fluorophenyl)sulfonyl]-2,3-dihydro-3-{2-(1-methylethoxy)phenyl}-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-60-3 HCAPLUS
 CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1-

(phenylsulfonyl)-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 873955-61-4 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 873955-62-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 873955-63-6 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-(2-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 873955-64-7 HCPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-difluorophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 873955-65-8 HCPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)- (CA INDEX NAME)




RN 873955-66-9 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-1-[(2,4-difluorophenyl)sulfonyl]-3-(2-ethoxyphenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-
(CA INDEX NAME)




RN 873955-67-0 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(4-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-ethyl-1-piperazinyl)-
(CA INDEX NAME)




RN 873955-68-1 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(4-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-propyl-1-piperazinyl)-
(CA INDEX NAME)




RN 873955-70-5 HCAPLUS

CN 1-Piperidinecarboxamide, N-[5-cyano-3-(2-ethoxyphenyl)-1-[(4-fluorophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-(1-methylethyl)-1-piperazinyl)- (CA INDEX NAME)



RN 873956-46-8 HCAPLUS

CN 1-Piperazinecarboxamide, N-[1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5-methoxy-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT	873953-64-1P	873953-65-2P	873953-66-3P	873953-67-4P
	873953-68-5P	873953-69-6P	873953-70-9P	873953-71-0P
	873953-73-2P	873953-74-3P	873953-75-4P	873953-76-5P
	873953-78-7P	873953-79-8P	873953-80-1P	873953-81-2P
	873953-83-4P	873953-84-5P	873953-85-6P	873953-86-7P
	873953-88-9P	873953-89-0P	873953-90-3P	873953-91-4P
	873953-93-6P	873953-94-7P	873953-95-8P	873953-96-9P
	873953-98-1P	873953-99-2P	873954-00-8P	873954-01-9P
	873954-03-1P	873954-04-2P	873954-05-3P	873954-06-4P
	873954-08-6P	873954-09-7P	873954-10-0P	873954-11-1P
	873954-12-2P	873954-13-3P	873954-14-4P	873954-15-5P
	873954-17-7P	873954-18-8P	873954-20-2P	873954-22-4P
	873954-26-8P	873954-27-9P	873954-29-1P	873954-30-4P
	873954-31-5P	873954-32-6P	873954-33-7P	
	873954-34-8P	873954-35-9P	873954-36-0P	
	873954-37-1P	873954-38-2P	873954-39-3P	873954-40-6P
	873954-42-8P	873954-43-9P	873954-44-0P	873954-45-1P
	873954-46-2P	873954-47-3P	873954-48-4P	873954-49-5P
	873954-51-9P	873954-52-0P	873954-53-1P	873954-54-2P
	873954-56-4P	873954-57-5P	873954-58-6P	873954-59-7P
	873954-61-1P	873954-62-2P	873954-63-3P	
	873954-64-4P	873954-65-5P	873954-66-6P	
	873954-67-7P	873954-68-8P	873954-69-9P	873954-70-2P
	873954-72-4P	873954-73-5P	873954-74-6P	873954-75-7P
	873954-77-9P	873954-78-0P	873954-79-1P	873954-80-4P
	873954-81-5P	873954-82-6P	873954-83-7P	
	873954-84-8P	873954-85-9P	873954-86-0P	
	873954-87-1P	873954-88-2P	873954-89-3P	
	873954-90-6P	873954-91-7P	873954-92-8P	873954-93-9P
	873954-94-0P	873954-95-1P	873954-96-2P	873954-97-3P
	873954-98-4P	873954-99-5P	873955-00-1P	
	873955-01-2P	873955-02-3P	873955-03-4P	873955-04-5P
	873955-05-6P	873955-06-7P	873955-07-8P	873955-08-9P
	873955-09-0P	873955-10-3P	873955-11-4P	873955-12-5P
	873955-13-6P	873955-14-7P	873955-15-8P	
	873955-16-9P	873955-17-0P	873955-19-2P	873955-21-6P
	873955-23-8P	873955-25-0P	873955-26-1P	
	873955-27-2P	873955-29-4P	873955-30-7P	873955-31-8P
	873955-32-9P	873955-33-0P	873955-34-1P	873955-35-2P
	873955-37-4P	873955-38-5P	873955-39-6P	873955-40-9P
	873955-41-0P	873955-42-1P	873955-43-2P	
	873955-44-3P	873955-45-4P	873955-46-5P	
	873955-47-6P	873955-48-7P	873955-49-8P	873955-50-1P
	873955-51-2P	873955-52-3P	873955-53-4P	873955-54-5P
	873955-56-7P	873955-57-8P	873955-58-9P	873955-59-0P
	873955-60-3P	873955-61-4P	873955-62-5P	
	873955-63-6P	873955-64-7P	873955-65-8P	
	873955-66-9P	873955-67-0P	873955-68-1P	
	873955-69-2P	873955-70-5P	873955-71-6P	873956-46-8P

RL (PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses))

(preparation of phenylsulfonylindolones and related compds. for the treatment of vasopressin or oxytocin dependent diseases)


ACCESSION NUMBER: 2003:76773 HCPLUS Full-text
 DOCUMENT NUMBER: 138:137337
 TITLE: Preparation of N-phenylsulfonyl-1,3-dihydro-2H-indol-2-one derivatives containing piperazinylcarbonyl or homopiperazinylcarbonyl as vasopressin receptor inhibitors, their preparation and their therapeutic use
 INVENTOR(S): Di Malta, Alain; Garcia, Georges; Roux, Richard;
 Schootjes, Bruno; Serradeil-le Gal, Claudine;
 Tonnerre, Bernard; Wagnon, Jean
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008407	A2	20030130	WO 2002-FR2500	20020715
WO 2003008407	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2827604	A1	20030124	FR 2001-10359	20010717
FR 2827604	B1	20030919		
CA 2450437	A1	20030130	CA 2002-2450437	20020715
AU 2002340999	A1	20030303	AU 2002-340999	20020715
AU 2002340999	B2	20070301		
EP 1419150	A2	20040519	EP 2002-774822	20020715
EP 1419150	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011284	A	20040803	BR 2002-11284	20020715
CN 1533387	A	20040929	CN 2002-814262	20020715
JP 2004536131	T	20041202	JP 2003-513966	20020715
HU 2004001461	A2	20041228	HU 2004-1461	20020715
NZ 530144	A	20050324	NZ 2002-530144	20020715
AT 294171	T	20050515	AT 2002-774822	20020715
ES 2240814	T3	20051016	ES 2002-774822	20020715
ZA 2003009717	A	20041215	ZA 2003-9717	20031215
IN 2003DN02183	A	20060120	IN 2003-DN2183	20031215
NO 2004000219	A	20040317	NO 2004-219	20040116
MX 2004PA00507	A	20040723	MX 2004-PA507	20040116
US 20040180878	A1	20040916	US 2004-484370	20040116
US 7119086	B2	20061010		
HK 1061679	A1	20050722	HK 2004-104546	20040625
PRIORITY APPLN. INFO.:			FR 2001-10359	A 20010717
			WO 2002-FR2500	W 20020715

OTHER SOURCE(S): MARPAT 138:137337

ED Entered STN: 31 Jan 2003

GI




AB The invention concerns N-phenylsulfonyl-1,3-dihydro-2H-indole-2-one derivs. containing piperazinylcarbonyl or homopiperazinylcarbonyl (shown as I; variables defined below; e.g. 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one), as well as their addition salts with acids or organic salts, their solvates and/or hydrate(s), exhibiting affinity and selectivity for arginine-vasopressin V_{1b} receptors and/or for oxytocin receptors, and further, for certain compds., an affinity for V_{1a} receptors. The invention also concerns the method for preparing them, intermediate compds. (I without phenylsulfonyl) for their preparation, pharmaceutical compns. containing them and their use for preparing medicines. For I: n = 1 or 2; X = -CH₂-, -O-, -NH-, -O-CH₂-, -NH-CH₂-; -NH-CH₂-CH₂-; R₁ = halo, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, trifluoromethyl; R₂ = H, halo, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, trifluoromethyl, trifluoromethoxy; R₄ = H, halo, (C₁-C₃)alkyl, (C₁-C₃)alkoxy; R₅ = pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazol-2-yl, oxazol-2-yl, imidazol-2-yl; R₆ = (C₁-C₄)alkoxy; R₇ = (C₁-C₄)alkoxy. Compds. I exhibit inhibition concns. (IC₅₀) for V_{1a} and V_{1b} vasopressin receptors and for oxytocin receptors from 10⁻⁶ to 10⁻⁹ M and for V₂ receptors better than 10⁻⁶ M. About 40 examples of intermediate prepn. and 92 examples of preparation of I are included.

IT 492431-36-4P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-37-5P, (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-38-6P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)homopiperazine-1-carboxamide 492431-39-7P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)homopiperazine-1-carboxamide 492431-40-0P, (+)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-41-1P, (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-42-2P, (+)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-43-3P, (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-

pyridinyl)piperazine-1-carboxamide 492431-44-4P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)piperazine-1-carboxamide
 492431-45-5P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-trifluoromethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-46-8P,
 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]amino]-1,3-dihydro-2H-indol-2-one
 492431-49-3P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[3-oxo-3-[4-(2-pyridinyl)-1-piperazinyl]propyl]amino]-1,3-dihydro-2H-indol-2-one 492431-50-2P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridazinyl)piperazine-1-carboxamide 492431-51-3P
 , N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)piperazine-1-carboxamide 492431-53-5P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-55-7P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide
 492431-60-4P, N-[5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)piperazine-1-carboxamide 492431-61-5P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide
 492431-62-6P, N-[6-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-92-2P,
 N-[5-Chloro-6-(trifluoromethyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-2-yl)-1-piperazinecarboxamide 492432-03-8P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-2-yl)-1-piperazinecarboxamide
 492432-04-9P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-4-yl)-1-piperazinecarboxamide 492432-05-0P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyrimidin-2-yl)-1-piperazinecarboxamide 492432-06-1P,
 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[3-oxo-3-[4-(pyridin-4-yl)-1-piperazinyl]propyl]amino]-1,3-dihydro-2H-indol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of N-phenylsulfonyldihydroindolone derivs.
 containing piperazinylcarbonyl or homopiperazinylcarbonyl as vasopressin
 receptor inhibitors, their preparation and their therapeutic use)


RN 492431-36-4 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)



RN 492431-37-5 HCPLUS


CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-, (-)
(CA INDEX NAME)

Rotation (-).




RN 492431-38-6 HCPLUS

CN 1H-1,4-Diazepine-1-carboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]hexahydro-4-(2-pyridinyl)- (CA INDEX NAME)



RN 492431-39-7 HCPLUS


CN 1H-1,4-Diazepine-1-carboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-

yl]hexahydro-4-(4-pyridinyl)-
(CA INDEX NAME)

RN 492431-40-0 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(3-pyridinyl)-
, (+)- (CA INDEX NAME)


Rotation (+).



RN 492431-41-1 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(3-pyridinyl)-
, (-)- (CA INDEX NAME)


Rotation (-).



RN 492431-42-2 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-, (+)- (CA INDEX NAME)


Rotation (+).



RN 492431-43-3 HCPLUS


CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-, (-)- (CA INDEX NAME)

Rotation (-).




RN 492431-44-4 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-pyridinyl)- (CA INDEX NAME)




RN 492431-45-5 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-4-(4-pyridinyl)- (CA INDEX NAME)




RN 492431-48-8 HCPLUS


CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-3-[(2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl)amino]- (CA INDEX NAME)




RN 492431-49-9 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-3-[{3-oxo-3-[4-(2-pyridinyl)-1-piperazinyl]propyl}amino]-(CA INDEX NAME)




RN 492431-50-2 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(3-pyridazinyl)-(CA INDEX NAME)




RN 492431-51-3 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-4-(2-pyrimidinyl)-(CA INDEX NAME)



RN 492431-53-5 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-{2-(1-methylethoxy)phenyl}-2-oxo-1H-indol-3-yl]-4-(3-pyridinyl)-(CA INDEX NAME)




RN 492431-55-7 HCPLUS
 CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-{2-(1-methylethoxy)phenyl}-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-(CA INDEX NAME)




RN 492431-60-4 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-pyridinyl)-(CA INDEX NAME)




RN 492431-61-5 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-(CA INDEX NAME)




RN 492431-62-6 HCPLUS

CN 1-Piperazinecarboxamide, N-[6-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5-methyl-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-(CA INDEX NAME)




RN 492431-92-2 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-4-(2-pyridinyl)- (CA INDEX NAME)




RN 492432-03-8 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-4-(2-pyridinyl)- (CA INDEX NAME)




RN 492432-04-9 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(4-pyridinyl)-(CA INDEX NAME)




RN 492432-05-0 HCPLUS

CN 1-Piperazinecarboxamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-4-(2-pyrimidinyl)-(CA INDEX NAME)



RN 492432-06-1 HCPLUS

CN 2H-Indol-2-one, 5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-3-[[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]amino]-(CA INDEX NAME)




IIT 169039-30-9P, 3-Amino-5-chloro-3-(2-chlorophenyl)-1-[{(2,4-dimethoxyphenyl)sulfonyl}-1,3-dihydro-2H-indol-2-one] 169039-34-3P
, Phenyl [5-Chloro-3-(2-chlorophenyl)-1-[{(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-48-5P, Phenyl
[5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-49-6P,
3-Amino-5-chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-1,3-dihydro-1H-indol-2-one 492430-53-2P, (+)-3-Amino-5-chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-54-3P 492430-60-1P, Phenyl
(S)-[5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-61-2P, Phenyl
[5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-63-4P,
3-Amino-5-chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-64-5P, Phenyl
[5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-66-7P,
3-Amino-5-chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-1,3-dihydro-2H-indol-2-one 492430-67-8P, Phenyl
[5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-trifluoromethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-73-6P, 3-Amino-5-chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-trifluoromethyl-1,3-dihydro-2H-indol-2-one 492430-74-7P, Phenyl [6-Chloro-3-(2-chlorophenyl)-1-[{(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-80-5P, 3-Amino-6-chloro-3-(2-chlorophenyl)-1-[{(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-1,3-dihydro-2H-indol-2-one 492430-83-8P, 2-[{5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]acetic acid 492430-86-1P, 2-[{5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]acetic acid tert-butyl ester 492430-87-2P, 3-[{5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]propionic acid 492430-89-4P, 3-[{5-Chloro-1-[{(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]propionic acid tert-butyl ester 492433-07-5P 492433-08-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-phenylsulfonyldihydroindolone derivs. containing piperazinylcarbonyl or homopiperazinylcarbonyl as vasopressin receptor inhibitors, their preparation and their therapeutic use)


RN 169039-30-9 HCPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 169039-34-3 HCPLUS

CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-48-5 HCPLUS

CN Carbamic acid, [5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-49-6 HCPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)




RN 492430-53-2 HCAPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-, (+)- (CA INDEX NAME)

Rotation (+).




RN 492430-54-3 HCAPLUS
 CN Carbamic acid, [(3R)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 492430-60-1 HCAPLUS
 CN Carbamic acid, [(3S)-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-[2-(1-methylethoxy)phenyl]-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 492430-61-2 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-63-4 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 492430-64-5 HCPLUS
 CN Carbamic acid, [5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-6-methyl-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-66-7 HCAPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-6-methyl- (CA INDEX NAME)



RN 492430-67-8 HCAPLUS
 CN Carbamic acid, [5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-73-6 HCAPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)-6-(trifluoromethyl)- (CA INDEX NAME)




RN 492430-74-7 HCPLUS

CN Carbamic acid, [6-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-5-methyl-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 492430-80-5 HCPLUS

CN 2H-Indol-2-one, 3-amino-6-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-5-methyl- (CA INDEX NAME)




RN 492430-83-8 HCPLUS

CN Glycine, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 492430-86-1 HCPLUS


CN Glycine, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 492430-87-2 HCAPLUS

CN β -Alanine, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)


RN 492430-89-4 HCAPLUS

CN β -Alanine, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-(2-methoxyphenyl)-2-oxo-1H-indol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 492433-07-5 HCAPLUS


CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-[2-(1-methylethoxy)phenyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 492433-08-6 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-[2-(1-methylethoxy)phenyl]-, (-) (CA INDEX NAME)

Rotation (-).



IC ICM C07D401-12
 ICS C07D401-14; C07D403-12; A61K031-496; A61P013-00
 CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 27
 IT 492431-14-8P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-16-0P, 5-Chloro-3-(2-ethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-18-2P, (-)-5-Chloro-3-(2-isopropoxypyhenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-20-6P, 3-(2-Chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-3-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-22-8P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(2-Pyridinyl)-1-piperazinecarboxylate 492431-23-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-25-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-pyridinyl)-1-piperazinecarboxylate Fumarate (2:3) 492431-27-3P, (-)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-32-0P, (+)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-34-2P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(2-Pyridinyl)-1-piperazinecarboxylate

492431-35-3P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-36-4P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-37-5P,
 (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-38-6P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)homopiperazine-1-carboxamide 492431-39-7P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)homopiperazine-1-carboxamide 492431-40-8P, (+)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-41-1P,
 (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-42-2P, (+)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-43-3P,
 (-)-N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-44-4P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)piperazine-1-carboxamide 492431-45-5P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-trifluoromethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-46-6P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethoxy]-1,3-dihydro-2H-indol-2-one 492431-48-8P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]amino]-1,3-dihydro-2H-indol-2-one 492431-49-3P
 , 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[3-oxo-3-(2-pyridinyl)-1-piperazinyl]propylamino]-1,3-dihydro-2H-indol-2-one 492431-50-2P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridazinyl)piperazine-1-carboxamide 492431-51-3P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyrimidinyl)piperazine-1-carboxamide 492431-52-4P, 5-Chloro-3-(2-isopropoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-53-5P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(3-pyridinyl)piperazine-1-carboxamide 492431-55-7P
 , N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-56-8P, 5,6-Dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-57-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-58-0P,
 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-59-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-6-methoxy-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-60-4P, N-[5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(2-pyridinyl)piperazine-1-carboxamide 492431-61-5P,
 N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide

492431-62-6P, N-[6-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-pyridinyl)piperazine-1-carboxamide 492431-63-7P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-64-8P, 5,6-Dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-65-9P, 5-Chloro-3-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-66-0P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-3-[2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-67-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-68-2P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-homopiperazine]ethyl]-1,3-dihydro-2H-indol-2-one 492431-69-3P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(1,3-thiazol-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-70-6P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(3-Pyridinyl)-1-piperazinecarboxylate 492431-71-7P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(1,3-thiazol-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-72-8P, N-[5-Chloro-6-(trifluoromethyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-2-yl)-1-piperazinecarboxamide 492431-73-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyrazin-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-74-0P, 5,6-Dichloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-75-1P, 5-Chloro-6-methyl-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-76-2P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-77-3P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl 4-(pyridin-2-yl)-1-piperazinecarboxylate 492431-78-4P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl 4-(pyridin-4-yl)-1-piperazinecarboxylate 492431-79-5P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl 4-(pyridin-4-yl)-1-piperazinecarboxylate 492431-80-6P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-(trifluoromethyl)phenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl 4-(pyridin-4-yl)-1-piperazinecarboxylate 492432-01-6P 492432-02-7P, 5-Chloro-6-methoxy-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl 4-(pyridin-4-yl)-1-piperazinecarboxylate 492432-03-8P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-4-yl)-1-piperazinecarboxamide 492432-04-9P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyridin-4-yl)-1-piperazinecarboxamide 492432-05-0P, N-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-chlorophenyl)-2-oxo-1,3-dihydro-2H-indol-3-yl]-4-(pyrimidin-4-yl)-1-piperazinecarboxamide 492432-06-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[3-oxo-3-[4-(pyridin-4-yl)-1-piperazinyl]propyl]amino-1,3-dihydro-2H-indol-2-one 492432-07-2P, 5-Chloro-6-methyl-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492432-08-3P, 5-Chloro-1-[(2,4-

dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyrimidin-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492432-09-4P,
 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyridazin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one
 492432-10-7P, 5-Chloro-6-methyl-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492432-11-8P, (-)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride 492432-12-9P, (-)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one fumarate 492432-13-0P, (-)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one phosphate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-phenylsulfonyldihydroindolone derivs. containing piperazinylcarbonyl or homopiperazinylcarbonyl as vasopressin receptor inhibitors, their preparation and their therapeutic use)

IT 389-31-1P 583-19-7P, 1-Bromo-2-ethoxybenzene 701-07-5P,
 1-Bromo-2-isopropoxybenzene 1677-48-1P, 5,6-Dichloro-1H-indole-2,3-dione 13726-14-2P, 4-Chloro-3-methoxyaniline 16750-63-3P, 2-Methoxyphenylmagnesium bromide 18437-66-6P, tert-Butyl 4-Chlorophenylcarbamate 34803-68-4P, 1-(2-Piperazinyl)piperazine 36692-27-0P, 2-Chlorophenylmagnesium bromide 37393-77-4P, 5-Chloro-3-(2-fluorophenyl)-1,3-dihydro-2H-indol-2-one 41842-29-9P, 2-Ethoxyphenylmagnesium bromide 41842-32-4P, 2-Isopropoxypyhenylmagnesium bromide 62890-98-6P, 2,5-Dimethoxyphenylmagnesium bromide 66644-69-7P, Ethyl 2-(2-Methoxyphenyl)-2-oxoacetate 67980-77-2P, 1-(3-Pyridinyl)piperazine 107583-35-7P, 5-Chloro-6-methyl-1H-indole-2,3-dione 169039-30-9P, 3-Amino-5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-2H-indol-2-one 169039-34-3P, Phenyl [5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 169040-40-8P, 5-Chloro-3-hydroxy-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 169040-42-0P, 3-Amino-5-chloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 169040-43-1P, 3,5-Dichloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 194853-82-2P, 1-(4-Pyridinyl)homopiperazine 287114-32-3P, 1-(2-Pyridinyl)homopiperazine 352030-17-2P, tert-Butyl 4-Chloro-3-methylphenylcarbamate 352030-18-3P, 5-Chloro-3-hydroxy-3-(2-methoxyphenyl)-6-methyl-1,3-dihydro-2H-indol-2-one 352277-86-2P, Ethyl 2-(2,3-Dimethoxyphenyl)-2-oxoacetate 352277-89-5P, 5-Chloro-3-hydroxy-3-(2-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 352277-93-1P, tert-Butyl (4-Chloro-3-trifluoromethylphenyl)carbamate 352277-95-3P, 5-Chloro-3-hydroxy-3-(2-methoxyphenyl)-6-trifluoromethyl-1,3-dihydro-2H-indol-2-one 352278-98-6P, N-(4-Chloro-3-methoxyphenyl)-DL-2-chloromandelamide 352278-00-3P, 5-Chloro-3-(2-chlorophenyl)-6-methoxy-1,3-dihydro-2H-indol-2-one 352278-02-5P, 5-Chloro-3-(2-chlorophenyl)-3-hydroxy-6-methoxy-1,3-dihydro-2H-indol-2-one 352278-08-1P, 5-Chloro-3-(2-ethoxyphenyl)-3-hydroxy-1,3-dihydro-2H-indol-2-one 352278-12-7P, 5-Chloro-3-hydroxy-3-(2-trifluoromethoxyphenyl)-1,3-dihydro-2H-indol-2-one 352278-23-0P, 5,6-Dichloro-3-hydroxy-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 365525-97-9P, 5-Chloro-3-hydroxy-3-(2,5-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 365525-99-1P, 3,5-Dichloro-3-(2,5-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 383424-86-0P, 3-Bromo-5-chloro-3-(2-fluorophenyl)-1,3-dihydro-2H-indol-2-one 383424-87-1P 383425-05-6P, 3,5-Dichloro-3-(2-methoxyphenyl)-6-trifluoromethyl-1,3-dihydro-2H-indol-2-one 474417-23-7P, tert-Butyl

4-(1, 3-Thiazol-2-yl)-1-piperazinecarboxylate 492429-86-4P,
 2-[5-Chloro-3-(2-methoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492429-87-5P, 5-Chloro-3-(2-methoxyphenyl)-1, 3-dihydro-2H-indol-2-one 492429-88-6P, 2-[5-Chloro-3-(2-methoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492429-89-7P, 2-[5-Chloro-3-(2-ethoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492429-90-0P, 5-Chloro-3-(2-ethoxyphenyl)-1, 3-dihydro-2H-indol-2-one 492429-91-1P, 2-[5-Chloro-3-(2-ethoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492429-93-3P, 5-Chloro-3-hydroxy-3-(2-isopropoxypyhenyl)-1, 3-dihydro-2H-indol-2-one 492429-94-4P, 5-Chloro-3-(2-isopropoxypyhenyl)-1, 3-dihydro-2H-indol-2-one 492429-95-5P, 2-[5-Chloro-3-(2-isopropoxypyhenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492429-96-6P, 2-[5-Chloro-3-(2-isopropoxypyhenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492429-97-7P, (3R)-4, 4-Dimethyl-2-oxotetrahydro-3-furanyl 2-[5-Chloro-3-(2-isopropoxypyhenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetate 492429-98-8P, 2-[3-(2-Chlorophenyl)-5-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492429-99-9P, 3-(2-Chlorophenyl)-5-methyl-1, 3-dihydro-2H-indol-2-one 492430-00-9P, 2-[3-(2-Chlorophenyl)-5-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid methyl ester 492430-01-0P, 2-[5, 6-Dichloro-3-(2-methoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492430-02-1P, 5, 6-Dichloro-3-(2-methoxyphenyl)-1, 3-dihydro-2H-indol-2-one 492430-03-2P, 2-[5, 6-Dichloro-3-(2-methoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492430-04-3P, 2-[5-Chloro-3-(2-methoxyphenyl)-6-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492430-05-4P, 5-Chloro-3-(2-methoxyphenyl)-6-methyl-1, 3-dihydro-2H-indol-2-one 492430-06-5P, 2-[5-Chloro-3-(2-methoxyphenyl)-6-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492430-07-6P, 2-[5-Chloro-3-(2-isopropoxypyhenyl)-6-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid 492430-08-7P, Ethyl 2-[2-[(tert-butoxycarbonyl)amino]-5-chloro-4-methylphenyl]-2-oxoacetate 492430-09-8P, 5-Chloro-3-hydroxy-3-(2-isopropoxypyhenyl)-6-methyl-1, 3-dihydro-2H-indol-2-one 492430-10-1P, 5-Chloro-3-(2-isopropoxypyhenyl)-6-methyl-1, 3-dihydro-2H-indol-2-one 492430-11-2P, 2-[5-Chloro-3-(2-isopropoxypyhenyl)-6-methyl-2-oxo-2, 3-dihydro-1H-indol-3-yl]acetic acid ethyl ester 492430-12-3P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl phenyl carbonate 492430-13-4P, 5-Chloro-3-(2-methoxyphenyl)-3-[(trimethylsilyl)oxy]-1, 3-dihydro-2H-indol-2-one 492430-14-5P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-3-[(trimethylsilyl)oxy]-1, 3-dihydro-2H-indol-2-one 492430-15-6P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-hydroxy-3-(2-methoxyphenyl)-1, 3-dihydro-2H-indol-2-one 492430-16-7P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxypyhenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl phenyl carbonate 492430-17-8P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-1H-indole-2, 3-dione 492430-18-9P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-hydroxy-3-(2-isopropoxypyhenyl)-1, 3-dihydro-2H-indol-2-one 492430-19-0P, Phenyl 5-Chloro-3-(2-isopropoxypyhenyl)-2-oxo-3-[(phenoxy carbonyl)oxy]-1-indolinecarboxylate 492430-20-3P, 5-Chloro-3-(2-chlorophenyl)-1-[(2, 4-dimethoxyphenyl)sulfonyl]-2-oxo-2, 3-dihydro-1H-indol-3-yl phenyl carbonate 492430-21-4P, 5-Chloro-3-(2-chlorophenyl)-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-hydroxy-1, 3-dihydro-2H-indol-2-one 492430-22-5P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-2-oxo-2, 3-dihydro-1H-indol-3-yl phenyl carbonate 492430-23-6P, 5-Chloro-3-(2-fluorophenyl)-3-hydroxy-1, 3-dihydro-2H-indol-2-one 492430-24-7P, 5-Chloro-3-(2-fluorophenyl)-3-[(trimethylsilyl)oxy]-1, 3-dihydro-2H-indol-2-one 492430-25-8P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-3-[(trimethylsilyl)oxy]-1, 3-dihydro-2H-indol-2-one 492430-26-9P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-3-hydroxy-1, 3-dihydro-2H-indol-2-one 492430-27-0P, 5-Chloro-1-[(2, 4-dimethoxyphenyl)sulfonyl]-3-

(2-trifluoromethylphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl phenyl carbonate 492430-28-1P, 5-Chloro-3-hydroxy-3-(2-trifluoromethylphenyl)-1,3-dihydro-2H-indol-2-one 492430-29-2P, 5-Chloro-3-(2-trifluoromethylphenyl)-1,3-dihydro-2H-indol-2-one 492430-30-5P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-trifluoromethylphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-31-6P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-3-(2-trifluoromethylphenyl)-1,3-dihydro-2H-indol-2-one 492430-32-7P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-trifluoromethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl phenyl carbonate 492430-33-8P, 5-Chloro-3-(2-trifluoromethoxyphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-34-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-trifluoromethoxyphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-35-0P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-3-(2-trifluoromethoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-36-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl phenyl carbonate 492430-37-2P, 5-Chloro-3-(2-methoxyphenyl)-6-methyl-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-38-3P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-39-4P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-3-(2-methoxyphenyl)-6-methyl-1,3-dihydro-2H-indol-2-one 492430-40-7P, 5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-6-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl phenyl carbonate 492430-41-8P, 5-Chloro-3-(2-chlorophenyl)-6-methoxy-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-42-9P, 5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-6-methoxy-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-43-0P, 5-Chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-6-methoxy-1,3-dihydro-2H-indol-2-one 492430-44-1P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl phenyl carbonate 492430-45-2P, 5-Chloro-3-(2,5-dimethoxyphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-46-3P, 5-Chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one 492430-47-4P, 5-Chloro-3-(2,5-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-1,3-dihydro-2H-indol-2-one 492430-48-5P, Phenyl [5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-49-6P, 3-Amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-50-9P, (3R)-5-Chloro-3-[(1S)-2-hydroxy-1-phenylethyl]amino]-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-51-1P, (+)-3-Amino-5-chloro-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-53-2P, (+)-3-Amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-54-3P, 492430-55-4P, 3,5-Dichloro-3-(2-isopropoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-56-5P, (3R)-5-Chloro-3-[(1S)-2-hydroxy-1-phenylethyl]amino]-3-(2-isopropoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-57-6P, (3S)-5-Chloro-3-[(1S)-2-hydroxy-1-phenylethyl]amino]-3-(2-isopropoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-58-7P, Phenyl (S)-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-61-3P, Phenyl [5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-62-3P, 3-Amino-5-chloro-3-(2,5-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-63-4P, 3-Amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2,5-dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 492430-64-5P, Phenyl [5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-65-6P, 3-Amino-5-chloro-3-(2-

methoxyphenyl)-6-methyl-1,3-dihydro-2H-indol-2-one 492430-66-7P,
 3-Amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-
 methyl-1,3-dihydro-2H-indol-2-one 492430-67-8P, Phenyl
 [5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-
 trifluoromethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate 492430-68-9P,
 (3R)-5-Chloro-3-[(1S)-2-hydroxy-1-phenylethyl]amino]-3-(2-methoxyphenyl)-
 6-trifluoromethyl-1,3-dihydro-2H-indol-2-one 492430-72-5P,
 3-Amino-5-chloro-3-(2-methoxyphenyl)-6-trifluoromethyl-1,3-dihydro-2H-
 indol-2-one 492430-73-6P, 3-Amino-5-chloro-1-[(2,4-
 dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-6-trifluoromethyl-1,3-
 dihydro-2H-indol-2-one 492430-74-7P, Phenyl [6-Chloro-3-(2-
 chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-2-oxo-2,3-dihydro-
 1H-indol-3-yl]carbamate 492430-76-9P 492430-77-0P,
 6-Chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydroindol-2-one
 492430-78-1P, 3-Bromo-6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydro-2H-
 indol-2-one 492430-79-2P, 3-Amino-6-chloro-3-(2-chlorophenyl)-5-methyl-
 1,3-dihydro-2H-indol-2-one 492430-80-5P, 3-Amino-6-chloro-3-(2-
 chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-5-methyl-1,3-dihydro-2H-
 indol-2-one 492430-81-6P, 2-[15-Chloro-3-(2-isopropoxypyhenyl)-2-oxo-2,3-
 dihydro-1H-indol-3-yl]oxyacetic acid 492430-82-7P, 2-[15-Chloro-3-(2-
 isopropoxypyhenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]oxyacetic acid methyl
 ester 492430-83-8P, 2-[15-Chloro-1-[(2,4-
 dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-
 yl]amino]acetic acid 492430-84-9P, 2-[15-Chloro-3-(2-methoxyphenyl)-2-
 oxo-2,3-dihydro-1H-indol-3-yl]amino]acetic acid tert-butyl ester
 492430-86-1P, 2-[15-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-
 methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]acetic acid
 tert-butyl ester 492430-87-2P, 3-[15-Chloro-1-[(2,4-
 dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-
 yl]amino]propionic acid 492430-88-3P, 3-[15-Chloro-3-(2-methoxyphenyl)-2-
 oxo-2,3-dihydro-1H-indol-3-yl]amino]propionic acid tert-butyl ester
 492430-89-4P, 3-[15-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-
 methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino]propionic acid
 tert-butyl ester 492430-91-8P, 2-[5-Chloro-3-(2-fluorophenyl)-2-oxo-2,3-
 dihydro-1H-indol-3-yl]acetic acid ethyl ester 492430-92-9P,
 2-[5-Chloro-3-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]acetic acid
 492430-93-0P, 2-[5,6-Dichloro-3-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-
 indol-3-yl]acetic acid 492430-94-1P 492430-95-2P, 5,6-Dichloro-3-(2-
 fluorophenyl)-2-dihydro-2H-indol-2-one 492430-97-4P,
 2-[5,6-Dichloro-3-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]acetic
 acid ethyl ester 492430-98-5P, 2-[5-Chloro-3-(2,3-dimethoxyphenyl)-2-oxo-
 2,3-dihydro-1H-indol-3-yl]acetic acid 492430-99-6P, 5-Chloro-3-(2,3-
 dimethoxyphenyl)-1,3-dihydro-2H-indol-2-one 492431-00-2P,
 2-[5-Chloro-3-(2,3-dimethoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]acetic
 acid ethyl ester 492431-01-3P, 2-[5-Chloro-3-(2-ethoxyphenyl)-6-methyl-2-
 oxo-2,3-dihydro-1H-indol-3-yl]acetic acid 492431-02-4P,
 5-Chloro-3-(2-ethoxyphenyl)-3-hydroxy-6-methyl-1,3-dihydro-2H-indol-2-one
 492431-03-5P, 5-Chloro-3-(2-ethoxyphenyl)-6-methyl-1,3-dihydro-2H-indol-2-
 one 492431-04-6P, 2-[5-Chloro-3-(2-ethoxyphenyl)-6-methyl-2-oxo-2,3-
 dihydro-1H-indol-3-yl]acetic acid ethyl ester 492431-05-7P,
 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-ethoxyphenyl)-2-oxo-2,3-
 dihydro-1H-indol-3-yl phenyl carbonate 492431-06-8P,
 5-Chloro-3-(2-ethoxyphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-
 one 492431-07-9P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-
 ethoxyphenyl)-3-[(trimethylsilyl)oxy]-1,3-dihydro-2H-indol-2-one
 492431-08-0P, 5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-
 ethoxyphenyl)-3-hydroxy-1,3-dihydro-2H-indol-2-one 492431-10-4P,
 1-(3-Pyridazinyl)piperazine Trihydrochloride 492431-11-5P, tert-Butyl
 4-(6-Chloro-3-pyridazinyl)-1-piperazinecarboxylate 492431-12-6P,
 tert-Butyl 4-(3-Pyridazinyl)-1-piperazinecarboxylate 492431-13-7P,

1-(1,3-Thiazol-2-yl)piperazine Dihydrochloride 492431-15-9P,
 5-Chloro-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-17-1P,
 5-Chloro-3-(2-ethoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-19-3P,
 (+)-5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-21-7P,
 3-(2-Chlorophenyl)-5-methyl-3-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-28-4P, Phenyl
 5-Chloro-3-(2-isopropoxyphenyl)-2-oxo-3-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]oxy-1-indolinecarboxylate 492431-29-5P,
 (3R)-5-Chloro-1-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]carbonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-30-8P, (3S)-5-Chloro-1-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]carbonyl]-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-31-9P, (-)-5-Chloro-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-33-1P,
 (+)-5-Chloro-3-(2-isopropoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl 4-(4-Pyridinyl)-1-piperazinecarboxylate 492431-47-7P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-72-8P,
 5-Chloro-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyrazin-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-73-9P,
 5,6-Dichloro-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-74-0P,
 5,6-Dichloro-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-75-1P,
 5-Chloro-6-methyl-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-76-2P,
 5-Chloro-6-methyl-3-(2-methoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-77-3P,
 5-Chloro-6-methyl-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-78-4P,
 5-Chloro-3-(2-fluorophenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-80-8P,
 5,6-Dichloro-3-(2-fluorophenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-81-9P,
 5-Chloro-3-(2,3-dimethoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-82-0P,
 5-Chloro-3-(2-ethoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-83-1P,
 5-Chloro-6-methyl-3-(2-ethoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-84-2P,
 , 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-85-3P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-homopiperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-86-4P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyrimidin-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-87-5P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridazin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-88-6P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(thiazol-2-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-89-7P,
 5-Chloro-6-methyl-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-3-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-90-0P,
 (+)-5-Chloro-3-(2-fluorophenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492431-91-1P,
 5-Chloro-3-(2-isopropoxyphenyl)-3-[2-oxo-2-[4-(pyridin-4-yl)-1-piperazinyl]ethyl]-1,3-dihydro-2H-indol-2-one 492433-05-3P

492433-06-4P 492433-07-5P 492433-08-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-phenylsulfonyldihydroindolone derivs. containing piperazinylcarbonyl or homopiperazinylcarbonyl as vasopressin receptor inhibitors, their preparation and their therapeutic use)

L26 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:447537 HCAPLUS Full-text
 DOCUMENT NUMBER: 131:214155
 TITLE: Synthesis and reactions of N-protected 3-nitroindoles
 AUTHOR(S): Pelkey, Erin T.; Gribble, Gordon W.
 CORPORATE SOURCE: Dep. Chemistry, Dartmouth College, Hanover, NH, 03755,
 USA
 SOURCE: Synthesis (1999), (7), 1117-1122
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:214155

ED Entered STN: 21 Jul 1999

AB Treatment of N-protected indoles with AcNO₃ generated in situ at low temps. affords the corresponding 3-nitroindoles in good to excellent yields. Deprotection of 1-acetyl-3-nitroindole with DBU gives 3-nitroindole. Reaction of 5-chloro-3-nitro-1-(phenylsulfonyl)indole with CNCH₂CO₂Et and base affords the rearranged 5-chloro-1,8-dihydro-8-(phenylsulfonyl)pyrrolo[2,3-b]indole-2-carboxylate. In contrast, treatment of 3-nitro-1-indolecarboxylates with CNCH₂CO₂Et and base affords the expected pyrrolo[3,4-b]indoles, products of a normal Barton-Zard pyrrole synthesis.


IT 243454-89-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of N-protected nitroindoles)

RN 243454-89-9 HCAPLUS

CN Propanedioic acid, 2-[(2R,3S)-2,3-dihydro-3-nitro-1-(phenylsulfonyl)-1H-indol-2-yl]-, 1,3-diethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

IT 4770-03-0P, 3-Nitroindole 36728-89-9P 73282-17-4P 90915-23-4P
 198135-69-2P 198135-70-5P 198135-76-1P 243454-84-4P 243454-86-6P
 243454-87-7P 243454-88-8P 243454-89-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of N-protected nitroindoles)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L26 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:858609 HCPLUS Full-text
 DOCUMENT NUMBER: 123:256516
 ORIGINAL REFERENCE NO.: 123:45875a,45878a
 TITLE: Indol-2-one derivatives substituted in the 3-position by a nitrogenous group, their preparation, and pharmaceutical compositions containing them as vasopressin and/or oxytocin receptor ligands.
 INVENTOR(S): Wagnon, Jean; Tonnerre, Bernard; Di Malta, Alain;
 Roux, Richard; Amiel, Marie-Sophie; Serradeil-Legal,
 Claudine
 PATENT ASSIGNEE(S): Sanofi, Fr.
 SOURCE: Fr. Demande, 70 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2714378	A1	19950630	FR 1993-15638	19931224
FR 2714378	B1	19960315		
WO 9518105	A1	19950706	WO 1994-FR1528	19941223
W: JP, LT, SI, RW: AT, BE, CH,	US			
DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 687251	A1	19951220	EP 1995-905164	19941223
EP 687251	B1	20020227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08507092	T	19960730	JP 1994-517812	19941223
JP 3263081	B2	20020304	JP 1995-517812	19941223
AT 213727	T	20020315	AT 1995-905164	19941223
PT 687251	T	20020830	PT 1995-905164	19941223
ES 2173172	T3	20021016	ES 1995-905164	19941223
US 5594023	A	19970114	US 1995-500924	19950731
US 5773612	A	19980630	US 1996-640080	19960430
PRIORITY APPLN. INFO.:			FR 1993-15638	A 19931224
			WO 1994-FR1528	W 19941223
			US 1995-500924	A3 19950731

OTHER SOURCE(S): CASREACT 123:256516; MARPAT 123:256516

ED Entered STN: 17 Oct 1995
 GI




AB Title compds. I [R1, R2 = H, halo, alkyl, alkoxy, CF₃; R3 = alkyl, cycloalkyl, (di)alkylcyclohexyl, (un)substituted Ph; R4 = N3, alkylsulfonamido, (un)substituted NH₂, heterocyclyl; R5 = H, R6; R6 = halo, alkyl, CF₃, cyano, (di)(alkyl)aminomethyl, NO₂; (un)substituted amino, carboxy, carbamoyl, acyl, etc.; X = SO₂, CH₂; m = 1, and sometimes 2-4] and salts are claimed, and approx. 100 examples are given. The compds. have affinity for vasopressin and/or oxytocin receptors, and are useful for treating disorders of the central and peripheral nervous, cardiovascular, renal, and gastric systems, as well as sexual disorders. For example, bromination of 5-chloro-1,3-dihydro-3-phenylindol-2-one with Br₂ in CC₁₄ gave the 3-bromo derivative, which reacted with anhydrous NH₃ in Et₂O to give the 3-amino derivative. Treatment of this with NaH in DMF and then with 2,4-(MeO)₂C₆H₃SO₂Cl yielded title compound II. In a test for inhibition of binding of [³H]-arginine-vasopressin to bovine renal V₂ receptors, I had IC₅₀ down to 10-9 M.

IT 169040-63-5P 169040-64-6P 169040-65-7P
 169040-66-8P 169040-67-9P 169040-68-0P
 169040-69-1P 169040-70-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of indolone derivs. as vasopressin and/or oxytocin receptor ligands)


RN 169040-63-5 HCPLUS

CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-2,3-dihydro-1-[(4-nitrophenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169040-64-6 HCPLUS

CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]aminophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169040-65-7 HCPLUS

CN Carbamic acid, [4-[(5-chloro-3-(2-chlorophenyl)-2,3-dihydro-3-[(methoxycarbonyl)amino]-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169040-66-8 HCAPLUS

CN Carbanic acid, [4-[(3-(acetylamino)-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169040-67-9 HCAPLUS

CN Benzoic acid, 4-[(3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 169040-68-0 HCAPLUS


CN Benzoic acid, 4-[(3-(acetylamino)-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxy-, phenylmethyl ester (CA INDEX NAME)



RN 169040-69-1 HCPLUS
 CN Benzoic acid, 4-[{3-(acetylamino)-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl}sulfonyl]-3-methoxy- (CA INDEX NAME)



RN 169040-70-4 HCPLUS
 CN Benzoic acid, 4-[{3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl}sulfonyl]-3-methoxy- (CA INDEX NAME)




IT 169039-28-5P 169039-29-6P 169039-30-9P
 169039-31-0P 169039-32-1P 169039-33-2P
 169039-34-3P 169039-35-4P 169039-36-5P
 169039-37-6P 169039-38-7P 169039-39-8P
 169039-40-1P 169039-41-2P 169039-42-3P
 169039-43-4P 169039-44-5P 169039-45-6P
 169039-46-7P 169039-47-8P 169039-48-9P
 169039-49-0P 169039-50-3P 169039-51-4P
 169039-52-5P 169039-53-6P 169039-54-7P
 169039-55-8P 169039-56-9P 169039-57-0P
 169039-58-1P 169039-59-2P 169039-60-5P
 169039-61-6P 169039-62-7P 169039-63-8P

169039-64-9P 169039-65-0P 169039-66-1P
 169039-67-2P 169039-68-3P 169039-69-4P
 169039-70-5P 169039-71-6P 169039-72-9P
 169039-73-0P 169039-74-1P 169039-75-2P
 169039-76-3P 169039-77-4P 169039-78-5P
 169039-79-6P 169039-80-9P 169039-81-0P
 169039-82-1P 169039-83-2P 169039-84-3P
 169039-85-4P 169039-86-5P 169039-87-6P
 169039-88-7P 169039-89-8P 169039-91-2P
 169039-92-3P 169039-93-4P 169039-94-5P
 169039-95-6P 169039-96-7P 169039-97-8P
 169039-98-9P 169039-99-0P 169040-00-0P
 169040-01-1P 169040-02-2P 169040-03-3P
 169040-04-4P 169040-05-5P 169040-07-7P
 169040-08-6P 169040-09-9P 169040-10-2P
 169040-11-3P 169040-20-4P 169040-21-5P
 169040-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indolone derivs. as vasopressin and/or oxytocin receptor ligands)


RN 169039-28-5 HCPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)




RN 169039-29-6 HCPLUS

CN Acetamide, N-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-30-9 HCPLUS


CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 169039-31-0 HCAPLUS
 CN Propanamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-32-1 HCAPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 169039-33-2 HCAPLUS
 CN Methanesulfonamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-34-3 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169039-35-4 HCPLUS
 CN 2H-Indol-2-one, 3-[(aminocarbonyl)amino]-5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 169039-36-5 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[(dimethylamino)carbonyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-37-6 HCAPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-
[(diethylamino)carbonyl]amino]-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-
dihydro- (9CI) (CA INDEX NAME)

RN 169039-38-7 HCAPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1,3-dihydro-1-[(4-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 169039-39-8 HCAPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-
[(diethylamino)carbonyl]amino]-1,3-dihydro-1-[(4-nitrophenyl)sulfonyl]-
(9CI) (CA INDEX NAME)

RN 169039-40-1 HCAPLUS


CN 2H-Indol-2-one, 1-[(4-aminophenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-3-
[(diethylamino)carbonyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-41-2 HCAPLUS
 CN Propanamide, N-[4-[(5-chloro-3-(2-chlorophenyl)-3-[(diethylamino)carbonyl]amino)-2,3-dihydro-2-oxo-1H-indol-1-yl]sulfonyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 169039-42-3 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-[(diethylamino)carbonyl]amino]-1-[{4-[(diethylamino)carbonyl]amino}phenyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-43-4 HCAPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 169039-44-5 HCAPLUS
 CN Carbamic acid, [4-[(3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxyphenyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 169039-45-6 HCAPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-2,3-dihydro-1-[(2-methoxy-4-[(phenoxy carbonyl)amino]phenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 169039-46-7 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-[[[(diethylamino)carbonyl]amino]-1-[[4-[(diethylamino)carbonyl]amino]-2-methoxyphenylsulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-47-8 HCPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)-2-methoxyphenylsulfonyl]-1,3-dihydro-(9CI) (CA INDEX NAME)




RN 169039-48-9 HCPLUS

CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-2,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]-2-oxo-1H-indol-3-yl], methyl ester (9CI) (CA INDEX NAME)




RN 169039-49-0 HCPLUS


CN Carbamic acid, [1-[(4-amino-2-methoxyphenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl], methyl ester (9CI) (CA INDEX NAME)




RN 169039-50-3 HCAPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)-2-methoxyphenyl]sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 169039-51-4 HCAPLUS
 CN Acetamide, N-[5-chloro-3-(2-chlorophenyl)-2,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-52-5 HCAPLUS
 CN Acetamide, N-[1-[(4-amino-2-methoxyphenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-53-6 HCPLUS
 CN Acetamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)-2-methoxyphenyl]sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-54-7 HCPLUS
 CN Benzamide, 4-[(3-(acetylamino)-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-N-(1,1-dimethylethyl)-3-methoxy- (CA INDEX NAME)




RN 169039-55-8 HCPLUS
 CN Benzanide, 4-[(3-amino-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-N-(1,1-dimethylethyl)-3-methoxy- (CA INDEX NAME)




RN 169039-56-9 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-1,3-dihydro-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 169039-57-0 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]methylamino)phenyl]sulfonyl]-3-(dimethylamino)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-58-1 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 169039-59-2 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-{[4-(ethylamino)-2-methoxyphenyl]sulfonyl}-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 169039-60-5 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-{[4-(diethylamino)-2-methoxyphenyl]sulfonyl}-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 169039-61-6 HCPLUS
 CN L-Alanine, N-[5-chloro-3-(2-chlorophenyl)-1-{[4-[(diethylamino)carbonyl]aminophenyl]sulfonyl}-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169039-62-7 HCAPLUS


CN L-Alanine, N-[5-chloro-3-(2-chlorophenyl)-1-[(4-((diethylamino)carbonyl)aminophenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169039-63-8 HCAPLUS

CN 2H-Indol-2-one, 3-amino-5-chloro-1-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-phenyl- (CA INDEX NAME)




RN 169039-64-9 HCAPLUS


CN 2H-Indol-2-one, 3-amino-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 169039-65-0 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(methylamino)- (CA INDEX NAME)



RN 169039-66-1 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro-3-(methylamino)- (CA INDEX NAME)




RN 169039-67-2 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]-3-(methylamino)- (CA INDEX NAME)




RN 169039-68-3 HCPLUS

CN 2H-Indol-2-one, 1-[{(4-amino-2-methoxyphenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-1,3-dihydro-3-(methylamino)- (CA INDEX NAME)




RN 169039-69-4 HCPLUS

CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[{[4-[(diethylamino)carbonyl]amino]-2-methoxyphenyl}sulfonyl]-1,3-dihydro-3-(methylamino)- (9CI) (CA INDEX NAME)



RN 169039-70-7 HCPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[{[4-[(diethylamino)carbonyl]amino]phenyl}sulfonyl]-3-(ethylamino)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-71-8 HCPLUS

CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[{[4-[(diethylamino)carbonyl]amino]phenyl}sulfonyl]-1,3-dihydro-3-


(propylamino)- (9CI) (CA INDEX NAME)



RN 169039-72-9 HCPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-
[(diethylamino)carbonyl]aminophenyl)sulfonyl]-1,3-dihydro-3-
(pentylamino)- (9CI) (CA INDEX NAME)

RN 169039-73-0 HCPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-
[(diethylamino)carbonyl]aminophenyl)sulfonyl]-3-[(1,1-
dimethylethyl)amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

RN 169039-74-1 HCPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-
[(diethylamino)carbonyl]aminophenyl)sulfonyl]-1,3-dihydro-3-[(2-
methylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 169039-75-2 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]aminophenyl)sulfonyl]-1,3-dihydro-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 169039-76-3 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(dimethylamino)-1,3-dihydro- (CA INDEX NAME)




RN 169039-77-4 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-(dimethylamino)-1,3-dihydro- (CA INDEX NAME)




RN 169039-78-5 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-(dimethylamino)-1,3-dihydro-1-[(4-nitrophenyl)sulfonyl]- (CA INDEX NAME)



RN 169039-79-6 HCPLUS
 CN 2H-Indol-2-one, 1-[(4-aminophenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-3-(dimethylamino)-1,3-dihydro- (CA INDEX NAME)




RN 169039-80-9 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-(dimethylamino)-1,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 169039-81-0 HCAPLUS

CN 2H-Indol-2-one, 1-[(4-amino-2-methoxyphenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-3-(dimethylamino)-1,3-dihydro- (CA INDEX NAME)




RN 169039-82-1 HCAPLUS

CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)-2-methoxyphenylsulfonyl]-3-(dimethylamino)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-83-2 HCAPLUS

CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-(diethylamino)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 169039-84-3 HCAPLUS


CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-(diethylamino)-1,3-dihydro-1-[(4-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 169039-85-4 HCPLUS
 CN 2H-Indol-2-one, 1-[(4-aminophenyl)sulfonyl]-5-chloro-3-(2-chlorophenyl)-3-(diethylamino)-1,3-dihydro- (CA INDEX NAME)




RN 169039-86-5 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-(diethylamino)-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-87-6 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-1,3-dihydro-3-[(2-methoxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 169039-88-7 HCAPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(4-
 [(diethylamino)carbonyl]amino)phenylsulfonyl]-3-[(2-
 (diethylamino)ethyl)amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-89-8 HCAPLUS
 CN Glycine, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-
 2,3-dihydro-2-oxo-1H-indol-3-yl]-, ethyl ester (CA INDEX NAME)




RN 169039-91-2 HCAPLUS
 CN Acetamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-
 dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX
 NAME)




RN 169039-92-3 HCPLUS
 CN Butanamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-3-methyl- (CA INDEX NAME)




RN 169039-93-4 HCPLUS
 CN Cyclohexanecarboxamide, N-[5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)




RN 169039-94-5 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 169039-95-6 HCPLUS
 CN Carbamic acid, [5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 169039-96-7 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-3-[[[[(2-(diethylamino)ethyl)methylamino]carbonyl]amino]-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-97-8 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-[[[[(2-(dimethylamino)ethyl)methylamino]carbonyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169039-98-9 HCAPLUS
 CN Acetamide, N-[5-chloro-3-(2-chlorophenyl)-1-[4-[(cycloheptylamino)carbonyl]amino]-2-methoxyphenylsulfonyl]-2,3-dihydro-2-oxo-1H-indol-3-yl]-(CA INDEX NAME)




RN 169039-99-0 HCAPLUS
 CN 4-Thiomorpholinecarboxamide, N-[4-[(3-(acetylamino)-5-chloro-3-(2-chlorophenyl)-2,3-dihydro-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxyphenyl]-(CA INDEX NAME)




RN 169040-00-0 HCAPLUS
 CN 2H-Indol-2-one, 3-azido-5-chloro-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]-1,3-dihydro- (CA INDEX NAME)




RN 169040-01-1 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]-3-(2-methoxyphenyl)- (CA INDEX NAME)




RN 169040-02-2 HCPLUS
 CN 2H-Indol-2-one, 3-amino-1-[(4-amino-2-methoxyphenyl)sulfonyl]-5-chloro-1,3-dihydro-3-(2-methoxyphenyl)- (CA INDEX NAME)




RN 169040-03-3 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[[4-[(diethylamino)carbonyl]amino]-2-methoxyphenylsulfonyl]-1,3-dihydro-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 169040-04-4 HCPLUS
 CN 2H-Indol-2-one, 5-chloro-1-[{4-[(diethylamino)carbonyl]amino}-2-methoxyphenylsulfonyl]-3-[(dimethylamino)carbonyl]amino]-1,3-dihydro-3-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 169040-05-5 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5-chloro-1-[{4-[(diethylamino)carbonyl]amino}phenylsulfonyl]-1,3-dihydro-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 169040-07-7 HCPLUS
 CN 2H-Indol-2-one, 3-amino-5,6-dichloro-1-[{4-[(diethylamino)carbonyl]amino}phenylsulfonyl]-1,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)



RN 169040-08-8 HCPLUS
 CN 2H-Indol-2-one, 3-amino-4,5-dichloro-1-[{4-[(diethylamino)carbonyl]amino}phenylsulfonyl]-1,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)




RN 169040-09-9 HCPLUS

CN 1,2-Hydrazinedicarboxylic acid, 1-[1-[(2,4-dimethoxyphenyl)sulfonyl]-5-ethoxy-2,3-dihydro-2-oxo-3-phenyl-1H-indol-3-yl]-, diethyl ester (9CI)
(CA INDEX NAME)


RN 169040-10-2 HCPLUS

CN 2H-Indol-2-one, 3-amino-3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-5-ethoxy-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 169040-11-3 HCPLUS


CN 2H-Indol-2-one, 3-amino-3-(2-chlorophenyl)-1-[(2,4-dimethoxyphenyl)sulfonyl]sulfonyl]-5-ethoxy-1,3-dihydro- (CA INDEX NAME)




RN 169040-20-4 HCPLUS
 CN Acetamide, N-[3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)phenyl]sulfonyl]-5-ethoxy-2,3-dihydro-2-oxo-1H-indol-3-yl]- (CA INDEX NAME)



RN 169040-21-5 HCPLUS
 CN 2H-Indol-2-one, 3-amino-3-(2-chlorophenyl)-5-ethoxy-1,3-dihydro-1-[(2-methoxy-4-nitrophenyl)sulfonyl]- (CA INDEX NAME)



RN 169040-22-6 HCPLUS
 CN Carbanic acid, [3-(2-chlorophenyl)-1-[(4-[(diethylamino)carbonyl]amino)-2-methoxyphenyl]sulfonyl]-5-ethoxy-2,3-dihydro-2-oxo-1H-indol-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



IC ICM C07D209-34

ICS C07D209-40; A61K031-40; A61K031-405

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT 1014-72-8P 13756-42-8P 20465-51-4P 59247-47-1P 60106-69-6P
 169040-23-7P 169040-24-8P 169040-25-9P 169040-26-0P 169040-27-1P
 169040-28-2P 169040-29-3P 169040-30-6P 169040-31-7P 169040-32-8P
 169040-33-9P 169040-34-0P 169040-35-1P 169040-36-2P 169040-37-3P
 169040-38-4P 169040-39-5P 169040-40-8P 169040-41-9P 169040-42-0P
 169040-43-1P 169040-44-2P 169040-45-3P 169040-46-4P 169040-47-5P
 169040-48-6P 169040-49-7P 169040-50-0P 169040-51-1P 169040-52-2P
 169040-53-3P 169040-54-4P 169040-55-5P 169040-56-6P 169040-57-7P
 169040-58-8P 169040-59-9P 169040-60-2P 169040-61-3P 169040-62-4P
 169040-63-5P 169040-64-6P 169040-65-7P
 169040-66-8P 169040-67-9P 169040-68-0P
 169040-69-1P 169040-70-4P 169040-71-5P 169040-72-6P
 169040-73-7P 169040-74-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indolone derivs. as vasopressin and/or oxytocin receptor ligands)

IT 169039-28-5P 169039-29-6P 169039-30-9P
 169039-31-0P 169039-32-1P 169039-33-2P
 169039-34-3P 169039-35-4P 169039-36-5P
 169039-37-6P 169039-38-7P 169039-39-8P
 169039-40-1P 169039-41-2P 169039-42-3P
 169039-43-4P 169039-44-5P 169039-45-6P
 169039-46-7P 169039-47-8P 169039-48-9P
 169039-49-0P 169039-50-3P 169039-51-4P
 169039-52-5P 169039-53-6P 169039-54-7P
 169039-55-8P 169039-56-9P 169039-57-0P
 169039-58-1P 169039-59-2P 169039-60-5P
 169039-61-6P 169039-62-7P 169039-63-8P
 169039-64-9P 169039-65-0P 169039-66-1P
 169039-67-2P 169039-68-3P 169039-69-4P
 169039-70-7P 169039-71-8P 169039-72-9P
 169039-73-0P 169039-74-1P 169039-75-2P
 169039-76-3P 169039-77-4P 169039-78-5P
 169039-79-6P 169039-80-9P 169039-81-0P
 169039-82-1P 169039-83-2P 169039-84-3P
 169039-85-4P 169039-86-5P 169039-87-6P
 169039-88-7P 169039-89-8P 169039-90-1P
 169039-91-2P 169039-92-3P 169039-93-4P
 169039-94-5P 169039-95-6P 169039-96-7P
 169039-97-8P 169039-98-9P 169039-99-0P
 169040-00-0P 169040-01-1P 169040-02-2P



169040-03-3P 169040-04-4P 169040-05-5P
 169040-06-6P 169040-07-7P 169040-08-8P
 169040-09-9P 169040-10-2P 169040-11-3P
 169040-12-4P 169040-13-5P 169040-14-6P 169040-15-7P 169040-16-8P
 169040-17-9P 169040-18-0P 169040-19-1P 169040-20-4P
 169040-21-5P 169040-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indolone derivs. as vasopressin and/or oxytocin receptor ligands)

L26 ANSWER 12 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:508506 HCPLUS Full-text
 DOCUMENT NUMBER: 121:108506
 ORIGINAL REFERENCE NO.: 121:19583a,19586a
 TITLE: Preparation of N-sulfonyl-2-oxoindoles as drugs having affinity for vasopressin and oxytocin receptors
 INVENTOR(S): Foulon, Loic; Garcia, Georges; Nisato, Dino; Roux, Richard; Serradeil-Legal, Claudine; Valette, Gerard; Wagnon, Jean
 PATENT ASSIGNEE(S): Elf Sanofi SA, Fr.
 SOURCE: PCT Int. Appl., 85 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9315051	A1	19930805	WO 1993-FR93	19930128
W: AU, BR, CA, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2686878	A1	19930806	FR 1992-1034	19920130
FR 2686878	B1	19950630		
CA 2107348	A1	19930731	CA 1993-2107348	19930128
AU 662960	A	19930901	AU 1993-35043	19930128
AU 662960	B2	19950921		
EP 581939	A1	19940209	EP 1993-904135	19930128
EP 581939	B1	19990602		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
BR 9303993	A	19940802	BR 1993-3993	19930128
JP 06507182	T	19940811	JP 1993-512992	19930128
HU 68642	A2	19950728	HU 1993-2762	19930128
AT 180773	T	19990615	AT 1993-904135	19930128
RU 2135469	C1	19990827	RU 1993-55882	19930128
ZA 9300649	A	19930902	ZA 1993-649	19930129
NO 9303482	A	19931129	NO 1993-3482	19930929
NO 180538	B	19970127		
NO 180538	C	19970507		
FI 9800341	A	19980213	FI 1998-341	19980213
PRIORITY APPLN. INFO.:			FR 1992-1034	A 19920130
			WO 1993-FR93	W 19930128
			FI 1993-4274	A 19930929

OTHER SOURCE(S): MARPAT 121:108506
 ED Entered STN: 03 Sep 1994
 GI




AB The title compds. I [R1, R2 = H, halo, alkyl, alkoxy, etc.; R3, R4 = alkyl, cycloalkyl, Ph, benzyl, etc.; or R3R4 = $(CH_2)_t X (CH_2)_l$; or CR3R4 = (substituted) hydrocarbon ring; or R1, R4 = as defined above, and R2R3 = $(CH_2)_3$ (in this case R2 is in position 4 of the indole ring); R5, R6 = H, halo, alkyl, cyano, etc.; m = 1; when R6 is halo, alkyl, alkoxy, m = 2 - 4; or (R6)m represents m substituents selected from halo, alkyl, alkoxy; t, l = 3 - 6; X = O, S, etc.] were prepared. Treatment of indolone II (R = H) with NaH, followed by reaction with 2-methoxy-4-nitrobenzenesulfonyl chloride gave indolone II (R = 2-methoxy-4-nitrobenzenesulfonyl). The title compds. in vitro had IC 50 values of 10-9 and 10-8 M against vasopressin and oxytocin binding, resp.

IT 156230-49-7P 156230-49-8P 156230-50-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)


RN 156230-48-7 HCPLUS

CN Benzanide, N-[5-chloro-2,3-dihydro-1-[(2-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-2,3-dimethyl- (CA INDEX NAME)




RN 156230-49-8 HCPLUS

CN Benzanide, N-[5-chloro-2,3-dihydro-1-[(4-methoxyphenyl)sulfonyl]-2-oxo-1H-indol-3-yl]-2-methyl- (CA INDEX NAME)



RN 156230-50-1 HCPLUS

CN Benzoic acid, 4-[(5-chloro-2,3-dihydro-3-[(2-methylbenzoyl)amino]-2-oxo-1H-indol-1-yl)sulfonyl]-3-methoxy-, methyl ester (CA INDEX NAME)



IC ICM C07D209-96

ICS A61K031-40; C07D209-90; C07D491-10; C07D471-10; C07D403-12; C07D409-12; C07D209-34

CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1

IT	156230-02-3P	156230-03-4P	156230-04-5P	156230-05-6P	156230-07-8P
	156230-08-9P	156230-09-0P	156230-10-3P	156230-11-4P	156230-12-5P
	156230-13-6P	156230-14-7P	156230-15-8P	156230-16-9P	156230-17-0P
	156230-18-1P	156230-19-2P	156230-20-5P	156230-21-6P	156230-22-7P
	156230-23-8P	156230-24-9P	156230-25-0P	156230-26-1P	156230-27-2P
	156230-28-3P	156230-29-4P	156230-30-7P	156230-31-8P	156230-32-9P
	156230-33-0P	156230-34-1P	156230-35-2P	156230-36-3P	156230-37-4P
	156230-38-5P	156230-39-6P	156230-40-9P	156230-41-0P	156230-42-1P
	156230-43-2P	156230-44-3P	156230-45-4P	156230-46-5P	156230-47-6P
	156230-48-7P	156230-49-8P	156230-50-1P		
	156230-51-2P	156230-52-3P	156230-53-4P	156230-54-5P	156230-55-6P
	156230-56-7P	156230-57-8P	156230-58-9P	156230-59-0P	156230-60-3P
	156230-61-4P	156230-62-5P	156230-63-6P	156230-64-7P	156230-65-8P
	156230-66-9P	156230-67-0P	156230-68-1P	156230-69-2P	156230-70-5P
	156230-71-6P	156230-72-7P	156230-73-8P	156230-74-9P	156230-75-0P
	156230-76-1P	156230-77-2P	156230-78-3P	156230-79-4P	156230-80-7P
	156230-81-8P	156230-82-9P	156230-83-0P	156230-84-1P	156230-85-2P
	156230-86-3P	156230-87-4P	156230-88-5P	156230-89-6P	156230-90-9P

156230-91-0P	156230-92-1P	156230-93-2P	156230-94-3P	156230-95-4P
156230-96-5P	156230-97-6P	156230-98-7P	156230-99-8P	156231-00-4P
156231-01-5P	156231-02-6P	156231-03-7P	156231-04-8P	156231-05-9P
156231-06-0P	156231-07-1P	156231-08-2P	156231-09-3P	156231-10-6P
156231-11-7P	156231-12-8P	156231-13-9P	156231-14-0P	156231-15-1P
156231-16-2P	156231-17-3P	156231-18-4P	156231-19-5P	156231-20-8P
156231-21-9P	156231-22-0P	156231-23-1P	156231-24-2P	156231-25-3P
156231-26-4P	156231-27-5P	156231-28-6P	156231-29-7P	156231-30-0P
156231-31-1P	156231-32-2P	156231-33-3P	156231-34-4P	156231-35-5P
156231-36-6P	156231-37-7P	156231-38-8P	156231-39-9P	156231-40-2P
156231-41-3P	156231-42-4P	156231-43-5P	156231-44-6P	156231-45-7P
156231-46-8P	156231-47-9P	156231-48-0P	156231-49-1P	156231-50-4P
156231-51-5P	156231-52-6P	156231-53-7P	156231-54-8P	156231-55-9P
156231-56-0P	156231-57-1P	156231-58-2P	156231-59-3P	156231-60-6P
156231-61-7P	156231-62-8P	156231-63-9P	156231-64-0P	156231-65-1P
156231-66-2P	156231-67-3P	156231-68-4P	156231-69-5P	156231-70-8P
156231-71-9P	156231-72-0P	156231-73-1P	156231-74-2P	156231-75-3P
156231-76-4P	156231-77-5P	156231-78-6P	156231-79-7P	156231-80-0P
156231-81-1P	156231-82-2P	156231-83-3P	156231-84-4P	156231-85-5P
156231-86-6P	156231-87-7P	156231-88-8P	156231-89-9P	156231-90-2P
156231-91-3P	156231-92-4P	156231-93-5P	156231-94-6P	156231-95-7P
156231-96-8P	156231-97-9P	156231-98-0P	156231-99-1P	156232-00-7P
156232-01-8P	156232-02-9P	156232-03-0P	156232-04-1P	156232-05-2P
156232-06-3P	156232-07-4P	156232-08-5P	156232-09-6P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)

L26 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979;151913 HCAPLUS Full-text

DOCUMENT NUMBER: 90:151913

ORIGINAL REFERENCE NO.: 90:24141a,24144a

TITLE: Reaction of benzo[b]furan and 1-acylindoles with iodine azide

AUTHOR(S): Tamura, Yasumitsu; Chun, Moon Woo; Kwon, Sundo; Bayomi, Said M.; Okada, Tomoko; Ikeda, Masazumi

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1978), 26(11), 3515-20

CODEN: CFBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 90:151913

ED Entered STN: 12 May 1984

AB Reaction of benzo[b]furan with IN3 gives in high yield a mixture of cis- and trans-2,3-diazido-2,3-dihydrobenzo[b]furans, both of which, upon treatment with alkali, are converted to 3-azidobenzo[b]furan. Similar reaction of 1-benzoyl- and 1-tosyl-2,3-diazidoindolines with IN3 affords high yields of cis- and trans-1-benzoyl- and 1-tosyl-2,3-diazidoindolines. Stereochem. assignment of the adducts is made based on NMR.

IT 69722-68-3P 69722-09-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cycloaddn. reaction of, with di-Me acetylenedicarboxylate)

RN 69722-08-3 HCAPLUS


CN 1H-Indole, 2,3-diazido-2,3-dihydro-1-[(4-methylphenyl)sulfonyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 69722-09-4 HCPLUS
 CN 1H-Indole, 2,3-diazido-2,3-dihydro-1-[(4-methylphenyl)sulfonyl]-, trans-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
 IT 57826-42-3P 57826-43-4P 69722-08-3P 69722-09-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cycloaddn. reaction of, with di-Me acetylenedicarboxylate)

L26 ANSWER 14 OF 14 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:4774 HCPLUS Full-text
 DOCUMENT NUMBER: 84:4774
 ORIGINAL REFERENCE NO.: 84:805a,808a
 TITLE: Reaction of iodine azide with 1-acylindoles.
 Formation of 1-acyl-cis- and trans-2,3-diazidoindolines
 AUTHOR(S): Tamura, Yasumitsu; Kwon, Sundo; Tabusa, Fujio; Ikeda, Masazumi
 CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Osaka, Japan
 SOURCE: Tetrahedron Letters (1975), (38), 3291-6
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 84:4774
 ED Entered STN: 12 May 1984
 GI For diagram(s), see printed CA Issue.
 AB Reaction in IN3 with 1-acylindoles I (R = Bz, R1 = H, R2 = Me; R1 = R2 = H, R1 = R2 = Me; R = SO2C6H4Me-p, CO2Et, R1 = H, R2 = Me) gave a mixture of the cis-II (R3 = R1, R4 = N3) and trans-diazidoindolines II (R3 = N3, R4 = R1). The indole I [R = Bz, R1R2 = (CH2)3] with IN3 gave adduct II [R2R3 = (CH2)3, R4 = N3]. The nonstereospecificity of the reaction of I (R1,R2 = H, Me) was due to

the formation of a carbonium ion which was attacked by N3- by an SN1 mechanism to give cis-II or trans-II.


IT 57826-46-7P 57826-47-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 57826-46-7 HCPLUS

CN 1H-Indole, 2,3-diazido-2,3-dihydro-3-methyl-1-[(4-methylphenyl)sulfonyl]-,
cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 57826-47-8 HCPLUS

CN 1H-Indole, 2,3-diazido-2,3-dihydro-3-methyl-1-[(4-methylphenyl)sulfonyl]-,
trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



CC 27-11 (Heterocyclic Compounds (One Hetero Atom))

IT 17017-58-2P 57826-40-1P 57826-41-2P 57826-42-3P 57826-43-4P

57826-44-5P 57826-45-6P 57826-46-7P 57826-47-8P

57826-48-9P 57826-49-0P 57826-50-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

=> d his nofile

(FILE 'HOME' ENTERED AT 10:58:10 ON 17 JUL 2008)

FILE 'HCAPLUS' ENTERED AT 10:58:40 ON 17 JUL 2008
 L1 1 SEA ABB=ON PLU=ON US20070185126/PN
 D IBIB AB IT SC
 SEL RN

FILE 'REGISTRY' ENTERED AT 10:59:33 ON 17 JUL 2008
 L2 106 SEA ABB=ON PLU=ON (1008-91-9/B1 OR 104-12-1/B1 OR 110-89-4/B1
 OR 126714-85-0/B1 OR 137049-02-6/B1 OR
 13726-69-7/B1 OR 14282-76-9/B1 OR 150020-64-7/B1 OR 16133-25-8/
 B1 OR 1628-89-3/B1 OR 16629-19-9/B1 OR 166964-35-8/B1 OR
 169040-40-8/B1 OR 169040-43-1/B1 OR 175205-72-8/B1 OR 17630-76-
 1/B1 OR 18704-37-5/B1 OR 1885-14-9/B1 OR 216394-05-7/B1 OR
 23995-88-2/B1 OR 2766-74-7/B1 OR 3149-28-8/B1 OR 337508-68-6/B1
 OR 342405-38-3/B1 OR 347888-57-7/B1 OR 34803-66-2/B1 OR
 352278-36-5/B1 OR 352278-37-6/B1 OR 368869-91-4/B1 OR 368869-93
 -6/B1 OR 51175-71-4/B1 OR 56686-16-9/B1 OR 576-83-0/B1 OR
 578-57-4/B1 OR 59340-27-1/B1 OR 620-08-6/B1 OR 63624-28-2/B1
 OR 66715-65-9/B1 OR 7295-76-3/B1 OR 80466-79-1/B1 OR 80466-80-4
 /B1 OR 848865-36-1/B1 OR 848865-38-3/B1 OR 848865-40-7/B1 OR
 848865-42-9/B1 OR 848865-44-1/B1 OR 848865-46-3/B1 OR 848865-48
 -5/B1 OR 848865-50-9/B1 OR 848865-52-1/B1 OR 848865-54-3/B1 OR
 848865-56-5/B1 OR 848865-57-6/B1 OR 848865-58-7/B1 OR 848865-59
 -8/B1 OR 848865-60-1/B1 OR 848865-61-2/B1 OR 848865-62-3/B1 OR
 848865-63-4/B1 OR 848865-64-5/B1 OR 848865-65-6/B1 OR 848865-66
 -7/B1 OR 848865-67-8/B1 OR 848865-68-9/B1 OR 848865-69-0/B1 OR
 848865-70-3/B1 OR 848865-71-4/B1 OR 848865-72-5/B1 OR 848865-73
 -6/B1 OR 848865-74-7/B1 OR 848865-75-8/B1 OR 848865-76-9/B1 OR
 848865-77-0/B1 OR 848865-78-1/B1 OR 848865-79-2/B1 OR 848865-80
 -5/B1 OR 848865-81-6/B1 OR 848865-82-7/B1 OR 848865-83-8/B1 OR
 848865-84-9/B1 OR 848865-85-0/B1 OR 848865-86-1/B1 OR 848865-87
 -2/B1 OR 848865-88-3/B1 OR 848865-89-4/B1 OR 848865-90-7/B1 OR
 848865-91-8/B1 OR 848865-92-9/B1 OR 848865-93-0/B1 OR 848865-94
 -1/B1 OR 848865-95-2/B1 OR 848865-96-3/B1 OR 848865-97-4/B1 OR
 848865-98-5/B1 OR 848865-99-6/B1 OR 848866-00-2/B1 OR 848866-20
 -6/B1 OR 874959-68-9/B1 OR 88398-93-0/B1 OR 896735-53-8/B1 OR
 90001-64-2/B1 OR 944798-17-8/B1 OR 944799-36-4/B1 OR 944799-80-
 8/B1 OR 95-16-9/B1)

L3 STRUCTURE UPLOADED
 D
 L4 0 SEA SSS SAM L3

FILE 'STNGUIDE' ENTERED AT 11:01:28 ON 17 JUL 2008


FILE 'REGISTRY' ENTERED AT 11:02:08 ON 17 JUL 2008
 L5 STRUCTURE UPLOADED
 D
 L6 0 SEA SSS SAM L5

FILE 'STNGUIDE' ENTERED AT 11:03:26 ON 17 JUL 2008

FILE 'REGISTRY' ENTERED AT 11:04:01 ON 17 JUL 2008
 L7 STRUCTURE UPLOADED
 D
 L8 8 SEA SSS SAM L7

L9 STRUCTURE UPLOADED
D
L10 7 SEA SSS SAM L9
D SCAN
L11 STRUCTURE UPLOADED
D
L12 0 SEA SSS SAM L11
L13 159 SEA SSS FUL L9
SAVE TEMP L13 CHA211REGL4/A
L14 0 SEA ABB=ON PLU=ON L13 AND L2
L15 STRUCTURE UPLOADED
D
L16 0 SEA SSS SAM L15
L17 STRUCTURE UPLOADED
D
L18 0 SEA SSS SAM L17
L19 0 SEA SUB=L13 SSS SAM L17
L20 STRUCTURE UPLOADED
D

Uploading L8.str



chain nodes :
10 11 12 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-15 9-10 10-11 10-12 10-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
6-9 7-15 8-9 9-10 10-11 10-12
exact bonds :
5-7 7-8 10-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 14:Atom 15:CLASS

L21 11 SEA SSS SAM L20
L22 314 SEA SSS FUL L20
L23 0 SEA ABB=ON PLU=ON L22 AND L2
 SAVE TEMP L22 CHA211REGL8/A
L24 313 SEA ABB=ON PLU=ON L22 AND ?INDOL?/CNS
L25 0 SEA ABB=ON PLU=ON L22 AND DIHYDROINDOL?/CNS

FILE 'HCAPLUS' ENTERED AT 11:25:21 ON 17 JUL 2008

L26 14 SEA ABB=ON PLU=ON L22
 SAVE TEMP L26 CHA211HCAPI/A
 E LUBISCH WILFRIED/AU
L27 80 SEA ABB=ON PLU=ON ("LUBISCH W"/AU OR "LUBISCH WILFRIED"/AU)
 E HORNBURGER WILFRIED/AU
L28 67 SEA ABB=ON PLU=ON ("HORNBURGER W"/AU OR "HORNBURGER W F"/AU
 OR "HORNBURGER WILFRIED"/AU OR "HORNBURGER WILFRIED B"/AU)
 E OOST THORSTEN K/AU
L29 42 SEA ABB=ON PLU=ON ("OOST T"/AU OR "OOST THORSTEN"/AU OR
 "OOST THORSTEN K"/AU)
 E SAUER DARYL RICHARD/AU
L30 50 SEA ABB=ON PLU=ON ("SAUER DARYL"/AU OR "SAUER DARYL R"/AU OR
 "SAUER DARYL RICHARD"/AU)
 E UNGER LILIANE/AU
L31 118 SEA ABB=ON PLU=ON ("UNGER LILIANE"/AU OR "UNGER LILIANE
 DR"/AU OR "UNGER LILIANE V"/AU)
 E WERNET WOLFGANG/AU
L32 82 SEA ABB=ON PLU=ON ("WERNET W"/AU OR "WERNET WOLFANG"/AU OR
 "WERNET WOLFGANG"/AU)
 E GENESTE HERVE/AU
L33 52 SEA ABB=ON PLU=ON "GENESTE HERVE"/AU
L34 24 SEA ABB=ON PLU=ON L27 AND ((L28 OR L29 OR L30 OR L31 OR L32
 OR L33))
L35 29 SEA ABB=ON PLU=ON L28 AND ((L29 OR L30 OR L31 OR L32 OR
 L33))
L36 13 SEA ABB=ON PLU=ON L29 AND ((L30 OR L31 OR L32 OR L33))
L37 7 SEA ABB=ON PLU=ON L30 AND ((L31 OR L32 OR L33))
L38 27 SEA ABB=ON PLU=ON L31 AND ((L32 OR L33))
L39 13 SEA ABB=ON PLU=ON L32 AND L33
L40 51 SEA ABB=ON PLU=ON ((L34 OR L35 OR L36 OR L37 OR L38 OR L39))
L41 13 SEA ABB=ON PLU=ON L40 AND (VASOPRESSIN RECEPTOR?)
L42 13 SEA ABB=ON PLU=ON L40 AND (VASOPRESSIN? OR OXYTOCIN?)
L43 8 SEA ABB=ON PLU=ON L42 NOT L26
 SAVE TEMP L43 CHA211HCAIN/A

FILE 'REGISTRY' ENTERED AT 11:36:59 ON 17 JUL 2008

L44 0 SEA ABB=ON PLU=ON L22 AND (MEDLINE/LC OR BIOSIS/LC OR
 DRUGU/LC OR EMBASE/LC)

FILE 'MEDLINE, BIOSIS, DRUGU, EMBASE' ENTERED AT 11:37:51 ON 17 JUL 2008

L45 39 SEA ABB=ON PLU=ON LUBISCH WILFRIED/AU
L46 46 SEA ABB=ON PLU=ON HORNBURGER WILFRIED/AU
L47 21 SEA ABB=ON PLU=ON OOST THORSTEN K/AU
L48 1 SEA ABB=ON PLU=ON SAUER DARYL RICHARD/AU
L49 57 SEA ABB=ON PLU=ON UNGER LILIANE/AU
L50 21 SEA ABB=ON PLU=ON WERNET WOLFGANG/AU
L51 38 SEA ABB=ON PLU=ON GENESTE HERVE/AU
L52 6 SEA ABB=ON PLU=ON L45 AND ((L46 OR L47 OR L48 OR L49 OR L50

OR L51))
 L53 21 SEA ABB=ON PLU=ON L46 AND ((L47 OR L48 OR L49 OR L50 OR
 L51))
 L54 0 SEA ABB=ON PLU=ON L47 AND ((L48 OR L49 OR L50 OR L51))
 L55 0 SEA ABB=ON PLU=ON L48 AND ((L49 OR L50 OR L51))
 L56 16 SEA ABB=ON PLU=ON L49 AND (L50 OR L51)
 L57 9 SEA ABB=ON PLU=ON L50 AND L51
 L58 0 SEA ABB=ON PLU=ON ((L52 OR L53 OR L54 OR L55 OR L56 OR L57))
 AND (VASOPRESSIN? OR OXYTOCIN?)
 L59 39 SEA ABB=ON PLU=ON ((L52 OR L53 OR L54 OR L55 OR L56 OR L57))
 AND (DRUG# OR PRODRUG# OR PHARMAC? OR MEDICA?)
 L60 1 SEA ABB=ON PLU=ON L59 AND INDOL?
 L61 1 SEA ABB=ON PLU=ON ((L52 OR L53 OR L54 OR L55 OR L56 OR L57))
 AND INDOL?
 D TI AU
 L62 30 SEA ABB=ON PLU=ON L59 AND (ANTIDEPRESS? OR ANTAGON?)
 D TI AU 1-5
 L63 12 DUP REM L62 (18 DUPLICATES REMOVED)
 ANSWERS '1-9' FROM FILE MEDLINE
 ANSWERS '10-12' FROM FILE BIOSIS
 SAVE TEMP L63 CHA211MULTIN/A

FILE 'STNGUIDE' ENTERED AT 11:44:22 ON 17 JUL 2008
 D QUE L43
 D QUE L63

FILE 'HCAPLUS, MEDLINE, BIOSIS' ENTERED AT 11:45:17 ON 17 JUL 2008
 L64 20 DUP REM L43 L63 (0 DUPLICATES REMOVED)
 ANSWERS '1-8' FROM FILE HCAPLUS
 ANSWERS '9-17' FROM FILE MEDLINE
 ANSWERS '18-20' FROM FILE BIOSIS
 D L64 1-8 IBIB ABS HITSTR
 D L64 9-20 IBIB AB
 D QUE L26
 D L26 IBIB ED ABS HITSTR HITIND
 D L26 2-14 IBIB ED ABS HITSTR HITIND